[{"id":6530,"date":"2026-11-04T07:32:00","date_gmt":"2026-11-04T07:32:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/"},"modified":"2026-11-04T07:32:00","modified_gmt":"2026-11-04T07:32:00","slug":"egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/","title":{"rendered":"Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD"},"content":{"rendered":"<div class=\"mfn-body\">\n<p><strong>Stockholm den 4 november 2026. <\/strong>\u2013 Egetis Therapeutics AB (publ) (\u201dEgetis\u201d eller \u201dBolaget\u201d) (Nasdaq Stockholm: EGTX) meddelar idag att Bolaget, tillsammans med det hel\u00e4gda dotterbolaget Rare Thyroid Therapeutics International AB (RTTI), har ing\u00e5tt ett slutligt avtal om f\u00f6rs\u00e4ljning av sin Rare Pediatric Disease Priority Review Voucher (PRV) f\u00f6r en k\u00f6peskilling om 190 miljoner USD (cirka 1 900 miljoner SEK) f\u00f6re avdrag, vilken kommer att erh\u00e5llas i samband med att transaktionen slutf\u00f6rs. Tidigare \u00e4gare av RTTI har r\u00e4tt till cirka 50 procent av nettoint\u00e4kterna fr\u00e5n PRV:n i form av en till\u00e4ggsk\u00f6peskilling efter Egetis f\u00f6rv\u00e4rv av EMCITATE<sup>\u00ae<\/sup> (tiratricol) 2020.<\/p>\n<p>Egetis tilldelades PRV:n den 28 september 2026 i samband med att den amerikanska l\u00e4kemedelsmyndigheten FDA godk\u00e4nde EMCITATE f\u00f6r behandling av perifer tyreotoxikos hos vuxna och pediatriska patienter med monokarboxylattransport\u00f6r 8 (MCT8) brist.<\/p>\n<p>Transaktionen \u00e4r f\u00f6rem\u00e5l f\u00f6r sedvanliga villkor f\u00f6r slutf\u00f6rande, inklusive att den till\u00e4mpliga v\u00e4ntetiden enligt den amerikanska Hart-Scott-Rodino (HSR) Antitrust Improvements Act l\u00f6per ut.<\/p>\n<p><strong>Om Egetis Therapeutics<\/strong><br \/>Egetis Therapeutics \u00e4r ett l\u00e4kemedelsbolag i kommersiell fas med fokus p\u00e5 att utveckla och tillhandah\u00e5lla innovativa behandlingar f\u00f6r patienter med s\u00e4llsynta sjukdomar d\u00e4r det finns betydande medicinska behov.<br \/>Genom att kombinera vetenskaplig och klinisk expertis med integrerade kompetenser inom sen klinisk utveckling, regulatoriska processer, kommersialisering och tillverkning \u00e4r Egetis engagerat i att tillhandah\u00e5lla behandlingar och dedikerat st\u00f6d till patientgrupper med stora medicinska behov och begr\u00e4nsade behandlingsalternativ. Bolagets ledande produkt, EMCITATE\u00ae (tiratricol), \u00e4r den f\u00f6rsta och enda godk\u00e4nda behandlingen f\u00f6r perifer tyreotoxikos hos patienter med MCT8-brist, en s\u00e4llsynt och livsf\u00f6rkortande genetisk sjukdom. EMCITATE har marknadsgodk\u00e4nnande i EU och i USA.<br \/>Med huvudkontor i Stockholm och verksamhet i USA och Europa bygger Egetis ett h\u00e5llbart globalt l\u00e4kemedelsbolag inom s\u00e4llsynta sjukdomar. F\u00f6r mer information, bes\u00f6k www.egetis.com och f\u00f6lj Bolaget p\u00e5 LinkedIn.<\/p>\n<p><strong>Fram\u00e5tblickande uttalanden<\/strong><br \/>Detta pressmeddelande inneh\u00e5ller fram\u00e5tblickande uttalanden i den mening som avses i till\u00e4mplig v\u00e4rdepapperslagstiftning, inklusive uttalanden avseende kommersialiseringen och tillg\u00e4ngligheten av Emcitate\u00ae (tiratricol) i USA, tidpunkten f\u00f6r och utfallet av en eventuell monetisering av Priority Review Voucher f\u00f6r s\u00e4llsynta pediatriska sjukdomar (Rare Pediatric Disease Priority Review Voucher), den f\u00f6rv\u00e4ntade kapaciteten i Bolagets infrastruktur f\u00f6r patient\u00e5tkomst och distribution, de f\u00f6rv\u00e4ntade f\u00f6rdelarna med Emcitate f\u00f6r patienter med MCT8-brist samt Bolagets \u00f6vergripande strategiska planer f\u00f6r utveckling och kommersialisering av behandlingar f\u00f6r s\u00e4llsynta sjukdomar. Fram\u00e5tblickande uttalanden kan i allm\u00e4nhet identifieras genom ord s\u00e5som \u201df\u00f6rv\u00e4ntar\u201d, \u201dbed\u00f6mer\u201d, \u201davser\u201d, \u201danser\u201d, \u201duppskattar\u201d, \u201dplanerar\u201d, \u201dkommer att\u201d, \u201dkan\u201d, \u201dskulle kunna\u201d, \u201dpotentiell\u201d eller liknande uttryck, \u00e4ven om inte alla fram\u00e5tblickande uttalanden inneh\u00e5ller s\u00e5dana ord.<br \/>Dessa uttalanden baseras p\u00e5 Bolagets nuvarande f\u00f6rv\u00e4ntningar, antaganden och bed\u00f6mningar per dagen f\u00f6r detta pressmeddelande och \u00e4r f\u00f6rem\u00e5l f\u00f6r risker, os\u00e4kerhetsfaktorer och andra omst\u00e4ndigheter som kan medf\u00f6ra att faktiska resultat avviker v\u00e4sentligt fr\u00e5n dem som uttryckligen eller underf\u00f6rst\u00e5tt anges i uttalandena. S\u00e5dana faktorer omfattar, men \u00e4r inte begr\u00e4nsade till, risker relaterade till den kommersiella lanseringen av och marknadsacceptansen f\u00f6r Emcitate i USA, Bolagets f\u00f6rm\u00e5ga att etablera och uppr\u00e4tth\u00e5lla en \u00e4ndam\u00e5lsenlig kommersiell infrastruktur, inklusive distributions-, patientst\u00f6ds- och ers\u00e4ttningsl\u00f6sningar, tidpunkten f\u00f6r och villkoren f\u00f6r en eventuell monetisering av Priority Review Voucher, vilken \u00e4r beroende av marknadsf\u00f6rh\u00e5llanden och tillg\u00e5ngen p\u00e5 intresserade k\u00f6pare, eventuella krav eller begr\u00e4nsningar efter marknadsgodk\u00e4nnande som kan komma att inf\u00f6ras av den amerikanska l\u00e4kemedelsmyndigheten FDA, Bolagets f\u00f6rm\u00e5ga att uppr\u00e4tth\u00e5lla regulatoriska godk\u00e4nnanden i USA och Europeiska unionen, konkurrens fr\u00e5n befintliga eller framtida behandlingar, Bolagets m\u00f6jlighet att s\u00e4kerst\u00e4lla tillr\u00e4cklig finansiering f\u00f6r sin verksamhet och sina kommersiella aktiviteter samt allm\u00e4nna ekonomiska, marknadsm\u00e4ssiga och aff\u00e4rsm\u00e4ssiga f\u00f6rh\u00e5llanden.<br \/>F\u00f6r en n\u00e4rmare beskrivning av risker och os\u00e4kerhetsfaktorer som kan p\u00e5verka Bolagets verksamhet och resultat h\u00e4nvisas till Bolagets senaste \u00e5rsredovisning samt \u00f6vriga handlingar som getts in till relevanta tillsynsmyndigheter och som finns tillg\u00e4ngliga p\u00e5 <a href=\"http:\/\/www.egetis.com.\/\" rel=\"noopener\" target=\"_blank\">www.egetis.com.<\/a><br \/>Bolaget \u00e5tar sig inte n\u00e5gon skyldighet att offentligt uppdatera eller revidera fram\u00e5tblickande uttalanden, vare sig till f\u00f6ljd av ny information, framtida h\u00e4ndelser eller av andra sk\u00e4l, annat \u00e4n vad som f\u00f6ljer av till\u00e4mplig lag eller regelverk.<\/p>\n<p><strong>F\u00f6r mer information, v\u00e4nligen kontakta<\/strong><br \/>Nicklas Westerholm, CEO<br \/>+46 (0) 733 542 062<br \/><a href=\"mailto:nicklas.westerholm@egetis.com\" rel=\"noopener\" target=\"_blank\">nicklas.westerholm@egetis.com<\/a><\/p>\n<p>Karl H\u00e5rd, Head of Investor Relations, Communications &amp; Business Development<br \/>+46 (0) 733 011 944<br \/><a href=\"mailto:karl.hard@egetis.com\" rel=\"noopener\" target=\"_blank\">karl.hard@egetis.com<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Egetis Therapeutics \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersoners f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2026-11-04 08:32 CET.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/fa4c6190-01e7-4f05-a554-daf661b72574\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd.pdf\" rel=\"noopener\" target=\"_blank\">Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"Stockholm den 4 november 2026. \u2013 Egetis Therapeutics AB (publ) (\u201dEgetis\u201d eller \u201dBolaget\u201d) (Nasdaq Stockholm: EGTX) meddelar idag att Bolaget, tillsammans med det hel\u00e4gda dotterbolaget Rare Thyroid Therapeutics International AB (RTTI), har ing\u00e5tt ett slutligt avtal om f\u00f6rs\u00e4ljning av sin Rare Pediatric Disease Priority Review Voucher (PRV) f\u00f6r en k\u00f6peskilling om 190 miljoner USD (cirka [&hellip;]","protected":false},"template":"","class_list":["post-6530","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ca","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn","mfn-news-tag-mfn-ca-other","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-lang-sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"Stockholm den 4 november 2026. \u2013 Egetis Therapeutics AB (publ) (\u201dEgetis\u201d eller \u201dBolaget\u201d) (Nasdaq Stockholm: EGTX) meddelar idag att Bolaget, tillsammans med det hel\u00e4gda dotterbolaget Rare Thyroid Therapeutics International AB (RTTI), har ing\u00e5tt ett slutligt avtal om f\u00f6rs\u00e4ljning av sin Rare Pediatric Disease Priority Review Voucher (PRV) f\u00f6r en k\u00f6peskilling om 190 miljoner USD (cirka [&hellip;]\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minuter\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\\\/\",\"name\":\"Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-11-04T07:32:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/","og_locale":"sv_SE","og_type":"article","og_title":"Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD - Egetis Therapeutics","og_description":"Stockholm den 4 november 2026. \u2013 Egetis Therapeutics AB (publ) (\u201dEgetis\u201d eller \u201dBolaget\u201d) (Nasdaq Stockholm: EGTX) meddelar idag att Bolaget, tillsammans med det hel\u00e4gda dotterbolaget Rare Thyroid Therapeutics International AB (RTTI), har ing\u00e5tt ett slutligt avtal om f\u00f6rs\u00e4ljning av sin Rare Pediatric Disease Priority Review Voucher (PRV) f\u00f6r en k\u00f6peskilling om 190 miljoner USD (cirka [&hellip;]","og_url":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/","og_site_name":"Egetis Therapeutics","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"4 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/","url":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/","name":"Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-11-04T07:32:00+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":6531,"date":"2026-11-04T07:32:00","date_gmt":"2026-11-04T07:32:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/"},"modified":"2026-11-04T07:32:00","modified_gmt":"2026-11-04T07:32:00","slug":"egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/","title":{"rendered":"Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million"},"content":{"rendered":"<div class=\"mfn-body\">\n<p><strong>Stockholm, Sweden, November 4, 2026. <\/strong>\u2013 Egetis Therapeutics AB (publ) (&#034;Egetis&#034; or the &#034;Company&#034;) (Nasdaq Stockholm: EGTX), today announced that the Company, together with its wholly-owned subsidiary Rare Thyroid Therapeutics International AB (RTTI), has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of USD 190 million (approximately SEK 1,900 million). Upon the closing of the transaction former owners of RTTI are entitled to approximately 50 percent of net proceeds of the PRV, as an earnout following Egetis\u2019 acquisition of EMCITATE<sup>\u00ae<\/sup> (tiratricol) in 2020.<\/p>\n<p>Egetis was granted the PRV on September 28, 2026, in connection with the U.S. Food and Drug Administration (FDA) approval of EMCITATE for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency.<\/p>\n<p>The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act.<\/p>\n<p><strong>About Egetis Therapeutics<\/strong><br \/>Egetis Therapeutics is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need.<\/p>\n<p>Combining scientific and clinical expertise with integrated late-stage development, regulatory and commercial capabilities, and manufacturing expertise, Egetis is committed to delivering treatments and dedicated support to underserved patient communities. The Company&#039;s lead product, EMCITATE<sup>\u00ae<\/sup> (tiratricol), is the first and only approved treatment of peripheral thyrotoxicosis in patients with MCT8 deficiency, a rare and life-shortening genetic disorder. EMCITATE holds marketing authorizations in the EU and in the U.S. \u00a0<\/p>\n<p>Headquartered in Stockholm, Sweden, with operations in the U.S. and Europe, Egetis is building a sustainable global rare disease company.<\/p>\n<p>For more information, visit egetis.com and follow the Company on LinkedIn.<\/p>\n<p><strong>Forward-Looking Statements<\/strong><br \/>This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the commercialization and availability of EMCITATE\u00ae (tiratricol) in the United States, the timing and outcome of potential monetization of the Rare Pediatric Disease Priority Review Voucher, the expected capabilities of the Company\u2019s patient access and distribution infrastructure, the anticipated benefits of EMCITATE for patients with MCT8 deficiency, and the Company\u2019s broader strategic plans for the development and commercialization of therapies for rare diseases. Forward-looking statements can generally be identified by words such as \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cplans,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cpotential,\u201d or similar expressions, although not all forward-looking statements contain these words.<\/p>\n<p>These statements are based on the Company\u2019s current expectations, assumptions, and assessments as of the date of this press release and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such factors include, but are not limited to: risks related to the commercial launch and market acceptance of EMCITATE in the United States; the ability to establish and maintain adequate commercial infrastructure, including distribution, patient support, and reimbursement arrangements; the timing and terms of any monetization of the Priority Review Voucher, which is subject to market conditions and the availability of interested purchasers; potential post-marketing requirements or restrictions imposed by the FDA; the ability to maintain regulatory approvals in the United States and the European Union; competition from existing or future therapies; the Company\u2019s ability to secure adequate funding for its operations and commercial activities; and general economic, market, and business conditions.<\/p>\n<p>For a further description of risks and uncertainties that could affect the Company\u2019s business and results, reference is made to the Company\u2019s most recent annual report and other filings with relevant regulatory authorities available at www.egetis.com. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law or regulation.<\/p>\n<p><strong>Investor contacts<\/strong><br \/>Nicklas Westerholm, CEO<br \/>+46 (0) 733 542 062<br \/>nicklas.westerholm@egetis.com<\/p>\n<p>Karl H\u00e5rd, Head of Investor Relations, Communications &amp; Business Development<br \/>+46 (0) 733 011 944<br \/>karl.hard@egetis.com<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>This information is information that Egetis Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-11-04 08:32 CET.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Attachments<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/369a492f-5574-4d17-b392-ad12628a3711\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million.pdf\" rel=\"noopener\" target=\"_blank\">Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"Stockholm, Sweden, November 4, 2026. \u2013 Egetis Therapeutics AB (publ) (&#034;Egetis&#034; or the &#034;Company&#034;) (Nasdaq Stockholm: EGTX), today announced that the Company, together with its wholly-owned subsidiary Rare Thyroid Therapeutics International AB (RTTI), has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of [&hellip;]","protected":false},"template":"","class_list":["post-6531","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ca","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn","mfn-news-tag-mfn-ca-other","mfn-news-tag-mfn-regulatory"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"Stockholm, Sweden, November 4, 2026. \u2013 Egetis Therapeutics AB (publ) (&#034;Egetis&#034; or the &#034;Company&#034;) (Nasdaq Stockholm: EGTX), today announced that the Company, together with its wholly-owned subsidiary Rare Thyroid Therapeutics International AB (RTTI), has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of [&hellip;]\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuter\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\\\/\",\"name\":\"Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-11-04T07:32:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/","og_locale":"sv_SE","og_type":"article","og_title":"Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million - Egetis Therapeutics","og_description":"Stockholm, Sweden, November 4, 2026. \u2013 Egetis Therapeutics AB (publ) (&#034;Egetis&#034; or the &#034;Company&#034;) (Nasdaq Stockholm: EGTX), today announced that the Company, together with its wholly-owned subsidiary Rare Thyroid Therapeutics International AB (RTTI), has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of [&hellip;]","og_url":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/","og_site_name":"Egetis Therapeutics","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"3 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/","url":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/","name":"Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-11-04T07:32:00+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":6518,"date":"2026-10-27T13:00:00","date_gmt":"2026-10-27T13:00:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/"},"modified":"2026-10-27T13:23:35","modified_gmt":"2026-10-27T13:23:35","slug":"egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/","title":{"rendered":"Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency"},"content":{"rendered":"<div class=\"mfn-body\">\n<ul>\n<li><strong>EMCITATE is the first and only FDA-approved treatment for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency in the United States<\/strong><strong><br \/><\/strong><\/li>\n<li><strong>Egetis RareLink\u2122, the dedicated patient support program, provides access assistance, education and care coordination in partnership with PANTHERx\u00ae Rare Pharmacy<\/strong><\/li>\n<\/ul>\n<p><strong>Stockholm, Sweden, October 27, 2026 <\/strong>\u2013 Egetis Therapeutics AB (publ) (\u201cEgetis\u201d or the \u201cCompany\u201d) (Nasdaq Stockholm: EGTX), a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases, today announced the commercial availability of EMCITATE<strong>\u00ae<\/strong> (tiratricol), ahead of anticipated timelines following U.S. Food and Drug Administration (FDA) approval on September 28, 2026.<\/p>\n<p>EMCITATE is indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan-Herndon-Dudley syndrome. It is the first and only FDA-approved treatment for MCT8 deficiency in the United States. EMCITATE is not recommended for the treatment of primary hypothyroidism.<\/p>\n<p><em>\u201cLaunching EMCITATE in the United States ahead of our anticipated timelines marks an important milestone for people living with MCT8 deficiency, their families and everyone who has worked toward bringing an approved treatment to this community,\u201d<\/em> <strong>said Nicklas Westerholm, chief executive officer of Egetis Therapeutics.<\/strong> <em>\u201cFollowing FDA approval, our focus is now on building on this momentum and helping eligible patients access treatment as quickly as possible. We remain deeply committed to the MCT8 deficiency community and grateful to the patients, families, clinicians, investigators and advocacy organizations that continue to support these efforts.\u201d<\/em><\/p>\n<p>MCT8 deficiency is a rare, devastating, life-limiting, X-linked disorder caused by pathogenic mutations in the <em>SLC16A2<\/em> gene. These mutations impair the function of MCT8, a critical cell-surface thyroid hormone transporter responsible for thyroid hormone transport in specific cells, including in the brain. The resulting disruption of thyroid hormone signaling leads to severe neurodevelopmental impairment and persistent peripheral thyrotoxicosis. Patients with MCT8 deficiency have a reported median life expectancy of approximately 35 years.<\/p>\n<p>To support the U.S. launch, Egetis has established Egetis RareLink, its dedicated patient support program, in partnership with PANTHERx Rare Pharmacy. The program is designed to help eligible patients, caregivers and health care professionals navigate medication access, education, care coordination and ongoing treatment services.<\/p>\n<p>Through Egetis RareLink, the Company aims to provide dedicated support and help eligible patients access EMCITATE. Patients and caregivers can learn more by calling 1-844-4EGETIS (1-844-434-3847) or go to <a href=\"https:\/\/www.emcitate.com\/\" rel=\"noopener\" target=\"_blank\">EMCITATE.com<\/a>.<\/p>\n<p><strong>About EMCITATE\u00ae<\/strong><br \/>EMCITATE (tiratricol) is a thyroid hormone receptor agonist indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan\u2013Herndon\u2013Dudley syndrome).<\/p>\n<p><strong>Limitation of use:<\/strong> EMCITATE is not recommended for the treatment of primary hypothyroidism.<\/p>\n<p><strong>About MCT8 Deficiency<\/strong><br \/>Monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan\u2013Herndon\u2013Dudley syndrome (AHDS), is a rare, devastating, life-limiting, X-linked disorder caused by pathogenic mutations in the <em>SLC16A2<\/em> gene. These mutations impair the function of MCT8, a critical cell-surface thyroid hormone transporter responsible for thyroid hormone transport in specific cells, including in the brain. Patients experience insufficient thyroid hormone activity in the central nervous system and excessive exposure to the active thyroid hormone triiodothyronine (T3) in peripheral tissues. This results in severe neurodevelopmental impairment and persistent peripheral thyrotoxicosis.<\/p>\n<p>Elevated T3 concentrations in peripheral tissues can result in a chronic hypermetabolic state affecting multiple organs, including the heart, muscles, liver and kidneys. Clinical manifestations may include failure to thrive, cardiovascular strain, muscle wasting, metabolic imbalance and increased susceptibility to infections. These systemic consequences are believed to contribute significantly to the increased morbidity and premature mortality associated with the disorder. Patients with MCT8 deficiency have a reported median life expectancy of approximately 35 years.<\/p>\n<p>For more information about MCT8 deficiency, visit <a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3DMCT8deficiency.com%26t%3Dh.eJxFjckKwjAURX-lZC2Jbaamq4Jrd_5AhhcbTAdCKgbx3yWouD33cO4T7SmioUFTzttAyPl06R34YAMstmC7zujQoFs17mDzmgqJAHpZ8LynbSrjl-ZHdYnhYJyQVEvGQRjqNG3BcuWplxqYIq1UHRNH2nMsBGtFp2ofaj_qT5KP11mH-Pt2dfuT1xv11jdB.MEUCIHg6doYCMEJhuKWMRFNHea5t4YAgM27qqNGISfcltg-DAiEAhom4KGuOBYCj0drrBTpmG36Msl-cLGPqTkMRh1eEM7w&amp;data=05|02|leeann.murphy%40vectorytx.com|749eb81b26b34499c81708df2e4b0656|48c522b05e5d4e2184f06ff6ad85c432|0|0|639280572207498216|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|0|||&amp;sdata=qdmkmjnaW5msUzXvptCQOxpt8yrRY3yGGD%2F7KkITvF8%3D&amp;reserved=0\" rel=\"noopener\" target=\"_blank\">MCT8deficiency.com<\/a> or <a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3DLifewithMCT8deficiency.com%26t%3Dh.eJxFjU0OwiAYBa_SsDbFlr_SVRO3uvMCFD4sEdqGUJUY726IGrfzJvOeaIse9RWaUlp7jI_Owt2l6XQ4dwas0w5mnWu9BLSr0LWYN9BpiRl7ADXPddjiOuXhS9OjuHhkMBouiBKUAR-JUaQBzaQlViigEjdCtpTvScdqzmnDW1n6UPpefZJsuATl_O_blO1PXm83Njp9.MEUCIQDA6ds0KCxxhOUSX7LGs-kFQey3hg3Ptclc34eJgEnVzAIgfJ6qbFF1u6RMx5WlpmB_46aeWQPcOLMs0wSoTED6Gq0&amp;data=05|02|leeann.murphy%40vectorytx.com|749eb81b26b34499c81708df2e4b0656|48c522b05e5d4e2184f06ff6ad85c432|0|0|639280572207523131|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|0|||&amp;sdata=g3IqD53R53SytRGIfA1bZND8umdRmOJFgLeKBXVvISQ%3D&amp;reserved=0\" rel=\"noopener\" target=\"_blank\">LifewithMCT8deficiency.com<\/a>.<\/p>\n<p><strong>Important Safety Information<\/strong><br \/><strong>BOXED WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS<\/strong><\/p>\n<p><strong>Contraindications:<\/strong> EMCITATE is contraindicated in patients with primary hyperthyroidism.<\/p>\n<p><strong>Warnings and precautions<\/strong><\/p>\n<ul>\n<li><strong>Thyrotoxicosis:<\/strong> Signs and symptoms of thyrotoxicosis, including increased heart rate, elevated blood pressure, diarrhea, hyperhidrosis, irritability, insomnia and nightmares, have occurred during treatment initiation and dose titration. Monitor patients and adjust the EMCITATE dose as indicated.<\/li>\n<li><strong>Laboratory test interference for T3 measurement:<\/strong> Tiratricol can cross-react with immunoassays for T3, leading to unreliable T3 results and overestimation of T3.<\/li>\n<\/ul>\n<p><strong>Adverse reactions:<\/strong> The most common adverse reactions (\u22655%) are diarrhea, vomiting, rash and hyperhidrosis. To report suspected adverse reactions, contact Egetis Therapeutics US Inc. at 1-844-4EGETIS (1-844-434-3847) or the FDA at 1-800-FDA-1088 or<a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3Dwww.fda.gov%26t%3Dh.eJxFzEsOgyAUheGtGMYNVHkVR27lChdpCmoMSk3TvTekTTo9_8n3IvsWSd-QkPPaM1ZKod4BnZaDJXQFsg3k0pBH_Rxo87KdLCLCPNO0b2s4h9-an9QuiY0SR6c0By0kqpE74C1aaTz3GlAY1mrTCXXlN0mVEq3qTPWx-hG-pBymBPdYvdpcbf_l_QGxgzhZ.MEUCIGwmDLgOpbTorJpKGnqkhEC08vn9CYT2zKuYs1CAJ34tAiEA0P_Ca3ZdskwDJjHtAeKrqA1_BJsXMHgebYmBSEbyW5Y&amp;data=05|02|leeann.murphy%40vectorytx.com|749eb81b26b34499c81708df2e4b0656|48c522b05e5d4e2184f06ff6ad85c432|0|0|639280572207547606|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|0|||&amp;sdata=tZ%2ByoYo0HXT0SMF9vcb1ifgONUb6a3h8Q6p6oxj%2Fe8o%3D&amp;reserved=0\" rel=\"noopener\" target=\"_blank\"> www.fda.gov\/medwatch<\/a>.<\/p>\n<p><strong>Please see the full Prescribing Information:<\/strong><a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3Dwww.egetis.com%26t%3Dh.eJxFzduOwiAUheFXMVxPYSqFTr3yVXZhU8lwCt21Yya-u0FNvP1X8q1_ttXATgd2ISrrSYh93zkuSH7lJkexl87kRJhIbCVksKvAaDwBYee2ELpScTXVzz4tnU8u1wjkc-LFOvZ1YL_NvqKhXG8iIEJKPG61XG7nd6W_59GscLZ6lDAOCvUsLcgejZqcdCPgMIl-nI6D_pY_ims99Po4NR-bH-BFqvMSwYfmtc227VPuD0rFTlk.MEQCIC_USug_zF2pxnijA76can_m8hy5uKqPlEVeGhwdcn96AiBa-iLK80TlSh3VCbbpLLKexX0cTp_2AE4Db63spOhogQ&amp;data=05|02|leeann.murphy%40vectorytx.com|749eb81b26b34499c81708df2e4b0656|48c522b05e5d4e2184f06ff6ad85c432|0|0|639280572207571099|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|0|||&amp;sdata=KPbzcRri95K8lJflYYHUD8Xm96OhlLvcaBQGTxU%2B3f0%3D&amp;reserved=0\" rel=\"noopener\" target=\"_blank\"> https:\/\/www.egetis.com\/wp-content\/uploads\/emcitate-full-prescribing-information.pdf<\/a><\/p>\n<p><strong>About Egetis Therapeutics<\/strong><br \/>Egetis Therapeutics is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need.<\/p>\n<p>Combining scientific and clinical expertise with integrated late-stage development, regulatory and commercial capabilities, and manufacturing expertise, Egetis is committed to delivering treatments and dedicated support to underserved patient communities. The Company\u2019s lead product, EMCITATE\u00ae (tiratricol), is the first and only approved treatment for MCT8 deficiency, a rare and life-shortening genetic disorder, with marketing authorizations in the European Union and the United States.<\/p>\n<p>Headquartered in Stockholm, Sweden, with operations in the U.S. and Europe, Egetis is building a sustainable global rare disease company.<\/p>\n<p>For more information, visit <a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3Degetis.com%26t%3Dh.eJxFjcsOwiAUBX-lYW1AClykq_4Kj9tHhLZBamyM_26IGrczJ3OeZM-RdA2ZStk6xnDEMt-oXxM5NeRazR19WfPBIqJdFpr2vE1H_6XlUbfMKXQBtLBaKgQnghUcvTKDGLRFaRjXppVwFhdFASSH1tQ-1n60n6Tqx2Tn-PsO1f3J6w0mmDST.MEQCIB4JZGYoog_uRKzv5LdNwb6ReHfGz_FTn5pTGzbeXG41AiA-rJrIwGw6DwwUWrZG0hy73aB7TG7Q0nP6Co0lbx77zw&amp;data=05|02|leeann.murphy%40vectorytx.com|749eb81b26b34499c81708df2e4b0656|48c522b05e5d4e2184f06ff6ad85c432|0|0|639280572207594861|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|0|||&amp;sdata=rUnWIy9VP1hKEiCssBtJrCLYGiGfWiMj0oII%2FvS7xHs%3D&amp;reserved=0\" rel=\"noopener\" target=\"_blank\">egetis.com<\/a> and follow the Company on LinkedIn.<\/p>\n<p><strong>About PANTHERx Rare<\/strong><br \/>PANTHERx Rare makes rare disease care more personalized and less overwhelming by focusing on each patient and each therapy. PANTHERx experts develop relationships with patients, prescribers and pharmaceutical partners, serving as trusted advocates to support collaboration and care. Founded in Pittsburgh, Pennsylvania, in 2011, PANTHERx has grown into the largest independent rare pharmacy in the U.S. PANTHERx is licensed in all 50 states and U.S. territories and was the first national pharmacy to achieve dual rare disease accreditations from the Accreditation Commission for Health Care (ACHC) and the Utilization Review Accreditation Commission (URAC). PANTHERx received the 2026 MMIT Patient Choice Award for patient satisfaction, marking its ninth win.<\/p>\n<p>For more information, visit<a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3Dwww.pantherxrare.com%26t%3Dh.eJxFjEsOwiAUAK_SsDYg5Sdd9Sqv8GqNlBJCbRvj3Q1q4nZmMk-y5kC6hkylpI6xbdtoglgmzHuGjNQtMyOnhtxr9EBXlnywgAgx0nnNaTr6Hy37Jx4UDl4bAUYq1IPwIDg6ZUcxGkBpGTe2lfosLopqLblubf1j_Qf4LlV_neEW6q86X92fvN4VDjjo.MEUCIB0HNNLiS7VhlxPx0j-xv2y3og9--PvO1KslZpSLB1K1AiEA0KwPOY7Oz-K6P8IUosuZbFb7x4TW1Ncqq5McauJUbjU&amp;data=05|02|leeann.murphy%40vectorytx.com|749eb81b26b34499c81708df2e4b0656|48c522b05e5d4e2184f06ff6ad85c432|0|0|639280572207618223|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|0|||&amp;sdata=bsKhLCi1D32XdwxUNPjvUW52z7WPtdo9lzVjUhI0S3I%3D&amp;reserved=0\" rel=\"noopener\" target=\"_blank\"> www.pantherxrare.com<\/a>.<\/p>\n<p><strong>For further information, please contact:<\/strong><br \/>Nicklas Westerholm, CEO<br \/>+46 (0) 733 542 062<br \/><a href=\"mailto:nicklas.westerholm@egetis.com\" rel=\"noopener\" target=\"_blank\">nicklas.westerholm@egetis.com<\/a><\/p>\n<p>Karl H\u00e5rd, Head of Investor Relations, Communications &amp; Business Development<br \/>+46 (0) 733 011 944<br \/><a href=\"mailto:karl.hard@egetis.com\" rel=\"noopener\" target=\"_blank\">karl.hard@egetis.com<\/a><\/p>\n<p><strong>Forward-Looking Statements<\/strong><br \/>This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the commercialization and availability of EMCITATE\u00ae (tiratricol) in the United States, the timing and outcome of potential monetization of the Rare Pediatric Disease Priority Review Voucher, the expected capabilities of the Company\u2019s patient access and distribution infrastructure, the anticipated benefits of EMCITATE for patients with MCT8 deficiency, and the Company\u2019s broader strategic plans for the development and commercialization of therapies for rare diseases. Forward-looking statements can generally be identified by words such as \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cplans,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cpotential,\u201d or similar expressions, although not all forward-looking statements contain these words.<br \/>These statements are based on the Company\u2019s current expectations, assumptions, and assessments as of the date of this press release and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such factors include, but are not limited to: risks related to the commercial launch and market acceptance of EMCITATE in the United States; the ability to establish and maintain adequate commercial infrastructure, including distribution, patient support, and reimbursement arrangements; the timing and terms of any monetization of the Priority Review Voucher, which is subject to market conditions and the availability of interested purchasers; potential post-marketing requirements or restrictions imposed by the FDA; the ability to maintain regulatory approvals in the United States and the European Union; competition from existing or future therapies; the Company\u2019s ability to secure adequate funding for its operations and commercial activities; and general economic, market, and business conditions.<br \/>For a further description of risks and uncertainties that could affect the Company\u2019s business and results, reference is made to the Company\u2019s most recent annual report and other filings with relevant regulatory authorities available at\u00a0<a href=\"http:\/\/www.egetis.com\/\" rel=\"noopener\" target=\"_blank\">www.egetis.com<\/a>. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law or regulation.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Attachments<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/21d74a82-5e26-4e75-9ece-d55d0d5b55f9\/egetis-therapeutics-announces-u-s-launch-of-emcitate-r-for-patients-with-mct8-deficiency.pdf\" rel=\"noopener\" target=\"_blank\">Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"EMCITATE is the first and only FDA-approved treatment for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency in the United States Egetis RareLink\u2122, the dedicated patient support program, provides access assistance, education and care coordination in partnership with PANTHERx\u00ae Rare Pharmacy Stockholm, Sweden, October 27, 2026 \u2013 Egetis Therapeutics AB (publ) (\u201cEgetis\u201d or [&hellip;]","protected":false},"template":"","class_list":["post-6518","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"EMCITATE is the first and only FDA-approved treatment for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency in the United States Egetis RareLink\u2122, the dedicated patient support program, provides access assistance, education and care coordination in partnership with PANTHERx\u00ae Rare Pharmacy Stockholm, Sweden, October 27, 2026 \u2013 Egetis Therapeutics AB (publ) (\u201cEgetis\u201d or [&hellip;]\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-27T13:23:35+00:00\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minuter\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\\\/\",\"name\":\"Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-10-27T13:00:00+00:00\",\"dateModified\":\"2026-10-27T13:23:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/","og_locale":"sv_SE","og_type":"article","og_title":"Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency - Egetis Therapeutics","og_description":"EMCITATE is the first and only FDA-approved treatment for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency in the United States Egetis RareLink\u2122, the dedicated patient support program, provides access assistance, education and care coordination in partnership with PANTHERx\u00ae Rare Pharmacy Stockholm, Sweden, October 27, 2026 \u2013 Egetis Therapeutics AB (publ) (\u201cEgetis\u201d or [&hellip;]","og_url":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2026-10-27T13:23:35+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"7 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/","url":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/","name":"Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-10-27T13:00:00+00:00","dateModified":"2026-10-27T13:23:35+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":6519,"date":"2026-10-27T13:00:00","date_gmt":"2026-10-27T13:00:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/"},"modified":"2026-10-27T13:23:36","modified_gmt":"2026-10-27T13:23:36","slug":"egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/","title":{"rendered":"Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist"},"content":{"rendered":"<div class=\"mfn-body\">\n<ul>\n<li><strong>EMCITATE \u00e4r den f\u00f6rsta och enda FDA-godk\u00e4nda behandlingen f\u00f6r perifer tyreotoxikos hos vuxna och pediatriska patienter med MCT8-brist i USA<\/strong><strong><br \/><\/strong><\/li>\n<li><strong>Egetis RareLink\u2122, det dedikerade patientst\u00f6dsprogrammet, erbjuder st\u00f6d kring tillg\u00e5ng till behandling, utbildning och v\u00e5rdkoordinering i samarbete med PANTHERx\u00ae Rare Pharmacy<\/strong><\/li>\n<\/ul>\n<p><strong>Stockholm den 27 oktober 2026 <\/strong>\u2013 Egetis Therapeutics AB (publ) (&#34;Egetis&#34; eller &#34;Bolaget&#34;) (Nasdaq Stockholm: EGTX), ett kommersiellt l\u00e4kemedelsbolag med fokus p\u00e5 att utveckla och tillhandah\u00e5lla innovativa behandlingar f\u00f6r patienter med s\u00e4llsynta sjukdomar, meddelade idag att EMCITATE\u00ae (tiratricol) nu \u00e4r kommersiellt tillg\u00e4ngligt i USA, tidigare \u00e4n f\u00f6rv\u00e4ntat efter godk\u00e4nnandet fr\u00e5n den amerikanska l\u00e4kemedelsmyndigheten FDA (US Food and Drug Administration) den 28 september 2026.<\/p>\n<p>EMCITATE \u00e4r godk\u00e4nt f\u00f6r behandling av perifer tyreotoxikos hos vuxna och pediatriska patienter med MCT8-brist, \u00e4ven k\u00e4nd som Allan-Herndon-Dudleys syndrom. Det \u00e4r den f\u00f6rsta och enda FDA-godk\u00e4nda behandlingen f\u00f6r MCT8-brist i USA. EMCITATE rekommenderas inte f\u00f6r behandling av prim\u00e4r hypotyreos.<\/p>\n<p><em>\u201dAtt lansera EMCITATE i USA tidigare \u00e4n v\u00e5r tidplan markerar en viktig milstolpe f\u00f6r personer som lever med MCT8-brist, deras familjer och alla som har arbetat f\u00f6r att g\u00f6ra en godk\u00e4nd behandling tillg\u00e4nglig f\u00f6r denna patientgrupp\u201d,<\/em> <strong>s\u00e4ger Nicklas Westerholm, vd f\u00f6r Egetis Therapeutics.<\/strong> <em>\u201dEfter FDA-godk\u00e4nnandet fokuserar vi nu p\u00e5 att bygga vidare p\u00e5 detta momentum och hj\u00e4lpa patienter att f\u00e5 tillg\u00e5ng till behandling s\u00e5 snabbt som m\u00f6jligt. Vi \u00e4r fortsatt djupt engagerade i dem som lider av MCT8-brist och tacksamma f\u00f6r det st\u00f6d vi f\u00e5r fr\u00e5n patienter, familjer, kliniker, pr\u00f6vare och patientorganisationer\u201d.<\/em><\/p>\n<p>MCT8-brist \u00e4r en s\u00e4llsynt, allvarlig, livsbegr\u00e4nsande, X-kromosombunden sjukdom som orsakas av sjukdomsframkallande mutationer i SLC16A2-genen. Dessa mutationer f\u00f6rs\u00e4mrar funktionen hos MCT8, ett viktigt transportprotein p\u00e5 cellmembranet som ansvarar f\u00f6r transport av sk\u00f6ldk\u00f6rtelhormon i vissa celler, inklusive i hj\u00e4rnan. Den st\u00f6rda signaleringen av sk\u00f6ldk\u00f6rtelhormon leder till sv\u00e5r neurologisk funktionsneds\u00e4ttning och ih\u00e5llande perifer tyreotoxikos. Patienter med MCT8-brist har en rapporterad medianlivsl\u00e4ngd p\u00e5 cirka 35 \u00e5r.<\/p>\n<p>Som st\u00f6d f\u00f6r lanseringen i USA har Egetis etablerat Egetis RareLink, bolagets dedikerade patientst\u00f6dsprogram, i samarbete med PANTHERx Rare Pharmacy. Programmet \u00e4r utformat f\u00f6r att hj\u00e4lpa ber\u00e4ttigade patienter, v\u00e5rdgivare och h\u00e4lso- och sjukv\u00e5rdspersonal att navigera fr\u00e5gor kring l\u00e4kemedelstillg\u00e5ng, utbildning, v\u00e5rdkoordinering och l\u00f6pande behandlingsst\u00f6d.<\/p>\n<p>Genom Egetis RareLink avser Bolaget att erbjuda personligt st\u00f6d och hj\u00e4lpa ber\u00e4ttigade patienter att f\u00e5 tillg\u00e5ng till EMCITATE\u00ae. Patienter och v\u00e5rdgivare kan f\u00e5 mer information genom att ringa 1\u2011844\u20114EGETIS (1\u2011844\u2011434\u20113847) eller bes\u00f6ka <a href=\"https:\/\/www.emcitate.com\/\" rel=\"noopener\" target=\"_blank\">EMCITATE.com.<\/a><\/p>\n<p><strong>Om EMCITATE\u00ae<\/strong><br \/>EMCITATE (tiratricol) \u00e4r en agonist till sk\u00f6ldk\u00f6rtelhormonreceptorn och \u00e4r godk\u00e4nd f\u00f6r behandling av perifer tyreotoxikos hos vuxna och pediatriska patienter med MCT8-brist, \u00e4ven kallad Allan\u2013Herndon\u2013Dudleys syndrom.<\/p>\n<p><strong>Om MCT8-brist<\/strong><strong><br \/><\/strong>MCT8-brist, \u00e4ven k\u00e4nd som Allan-Herndon-Dudleys syndrom (AHDS), \u00e4r en s\u00e4llsynt, allvarlig och livsf\u00f6rkortande X-kromosombunden sjukdom som orsakas av sjukdomsframkallande mutationer i SLC16A2-genen. Dessa mutationer f\u00f6rs\u00e4mrar funktionen hos MCT8, en viktig transport\u00f6r p\u00e5 cellernas yta som ansvarar f\u00f6r transport av sk\u00f6ldk\u00f6rtelhormon i vissa celler, inklusive i hj\u00e4rnan. Som en f\u00f6ljd av detta f\u00e5r patienterna en st\u00f6rd signalering av sk\u00f6ldk\u00f6rtelhormon, k\u00e4nnetecknad av otillr\u00e4cklig aktivitet av sk\u00f6ldk\u00f6rtelhormon i det centrala nervsystemet och \u00f6verexponering f\u00f6r det aktiva sk\u00f6ldk\u00f6rtelhormonet trijodtyronin (T3) i perifera v\u00e4vnader. Detta leder till en komplex sjukdomsbild som pr\u00e4glas av sv\u00e5r neurologisk utvecklingsst\u00f6rning och kvarst\u00e5ende perifer tyreotoxikos.<\/p>\n<p>De f\u00f6rh\u00f6jda T3-niv\u00e5erna i perifera v\u00e4vnader kan orsaka ett kroniskt hypermetaboliskt tillst\u00e5nd som p\u00e5verkar flera organ, inklusive hj\u00e4rta, muskler, lever och njurar. Kliniska manifestationer kan omfatta otillr\u00e4cklig tillv\u00e4xt, kardiovaskul\u00e4r belastning, muskelf\u00f6rtvining, metabol obalans samt \u00f6kad mottaglighet f\u00f6r infektioner. Dessa systemiska konsekvenser av ih\u00e5llande tyreotoxikos anses bidra v\u00e4sentligt till den \u00f6kade sjukligheten och den f\u00f6rkortade livsl\u00e4ngden som \u00e4r f\u00f6rknippad med sjukdomen. Patienter med MCT8-brist har en rapporterad medianlivsl\u00e4ngd p\u00e5 cirka 35 \u00e5r.<br \/>F\u00f6r mer information om MCT8-brist, bes\u00f6k \u00a0<a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3DMCT8deficiency.com%26t%3Dh.eJxFjckKwjAURX-lZC2Jbaamq4Jrd_5AhhcbTAdCKgbx3yWouD33cO4T7SmioUFTzttAyPl06R34YAMstmC7zujQoFs17mDzmgqJAHpZ8LynbSrjl-ZHdYnhYJyQVEvGQRjqNG3BcuWplxqYIq1UHRNH2nMsBGtFp2ofaj_qT5KP11mH-Pt2dfuT1xv11jdB.MEUCIHg6doYCMEJhuKWMRFNHea5t4YAgM27qqNGISfcltg-DAiEAhom4KGuOBYCj0drrBTpmG36Msl-cLGPqTkMRh1eEM7w&amp;data=05%7C02%7Cleeann.murphy%40vectorytx.com%7C749eb81b26b34499c81708df2e4b0656%7C48c522b05e5d4e2184f06ff6ad85c432%7C0%7C0%7C639280572207498216%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=qdmkmjnaW5msUzXvptCQOxpt8yrRY3yGGD%2F7KkITvF8%3D&amp;reserved=0\" rel=\"noopener\" target=\"_blank\">MCT8deficiency.com<\/a> eller <a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3DLifewithMCT8deficiency.com%26t%3Dh.eJxFjU0OwiAYBa_SsDbFlr_SVRO3uvMCFD4sEdqGUJUY726IGrfzJvOeaIse9RWaUlp7jI_Owt2l6XQ4dwas0w5mnWu9BLSr0LWYN9BpiRl7ADXPddjiOuXhS9OjuHhkMBouiBKUAR-JUaQBzaQlViigEjdCtpTvScdqzmnDW1n6UPpefZJsuATl_O_blO1PXm83Njp9.MEUCIQDA6ds0KCxxhOUSX7LGs-kFQey3hg3Ptclc34eJgEnVzAIgfJ6qbFF1u6RMx5WlpmB_46aeWQPcOLMs0wSoTED6Gq0&amp;data=05%7C02%7Cleeann.murphy%40vectorytx.com%7C749eb81b26b34499c81708df2e4b0656%7C48c522b05e5d4e2184f06ff6ad85c432%7C0%7C0%7C639280572207523131%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=g3IqD53R53SytRGIfA1bZND8umdRmOJFgLeKBXVvISQ%3D&amp;reserved=0\" rel=\"noopener\" target=\"_blank\">LifewithMCT8deficiency.com<\/a>.<br \/><strong>\u00a0<\/strong><br \/><strong>Important Safety Information<\/strong><br \/><strong>BOXED WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS<\/strong><br \/><strong>Contraindications:<\/strong> EMCITATE is contraindicated in patients with primary hyperthyroidism.<br \/><strong>\u00a0<\/strong><br \/><strong>Warnings and precautions<\/strong><\/p>\n<p>\u25cf\u00a0<strong>Thyrotoxicosis:<\/strong> Signs and symptoms of thyrotoxicosis, including increased heart rate, elevated blood pressure, diarrhea, hyperhidrosis, irritability, insomnia and nightmares, have occurred during treatment initiation and dose titration. Monitor patients and adjust the EMCITATE dose as indicated.<br \/>\u25cf\u00a0<strong>Laboratory test interference for T3 measurement:<\/strong> Tiratricol can cross-react with immunoassays for T3, leading to unreliable T3 results and overestimation of T3.<\/p>\n<p><strong>Adverse reactions:<\/strong> The most common adverse reactions (\u22655 %) are diarrhea, vomiting, rash and hyperhidrosis.<br \/>To report suspected adverse reactions, contact Egetis Therapeutics US Inc. at 1-844-4EGETIS (1-844-434-3847) or the FDA at 1-800-FDA-1088 or<a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3Dwww.fda.gov%26t%3Dh.eJxFzEsOgyAUheGtGMYNVHkVR27lChdpCmoMSk3TvTekTTo9_8n3IvsWSd-QkPPaM1ZKod4BnZaDJXQFsg3k0pBH_Rxo87KdLCLCPNO0b2s4h9-an9QuiY0SR6c0By0kqpE74C1aaTz3GlAY1mrTCXXlN0mVEq3qTPWx-hG-pBymBPdYvdpcbf_l_QGxgzhZ.MEUCIGwmDLgOpbTorJpKGnqkhEC08vn9CYT2zKuYs1CAJ34tAiEA0P_Ca3ZdskwDJjHtAeKrqA1_BJsXMHgebYmBSEbyW5Y&amp;data=05%7C02%7Cleeann.murphy%40vectorytx.com%7C749eb81b26b34499c81708df2e4b0656%7C48c522b05e5d4e2184f06ff6ad85c432%7C0%7C0%7C639280572207547606%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=tZ%2ByoYo0HXT0SMF9vcb1ifgONUb6a3h8Q6p6oxj%2Fe8o%3D&amp;reserved=0\" rel=\"noopener\" target=\"_blank\"> www.fda.gov\/medwatch<\/a>.<\/p>\n<p><strong>Please see the full Prescribing Information:<\/strong><a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3Dwww.egetis.com%26t%3Dh.eJxFzduOwiAUheFXMVxPYSqFTr3yVXZhU8lwCt21Yya-u0FNvP1X8q1_ttXATgd2ISrrSYh93zkuSH7lJkexl87kRJhIbCVksKvAaDwBYee2ELpScTXVzz4tnU8u1wjkc-LFOvZ1YL_NvqKhXG8iIEJKPG61XG7nd6W_59GscLZ6lDAOCvUsLcgejZqcdCPgMIl-nI6D_pY_ims99Po4NR-bH-BFqvMSwYfmtc227VPuD0rFTlk.MEQCIC_USug_zF2pxnijA76can_m8hy5uKqPlEVeGhwdcn96AiBa-iLK80TlSh3VCbbpLLKexX0cTp_2AE4Db63spOhogQ&amp;data=05%7C02%7Cleeann.murphy%40vectorytx.com%7C749eb81b26b34499c81708df2e4b0656%7C48c522b05e5d4e2184f06ff6ad85c432%7C0%7C0%7C639280572207571099%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=KPbzcRri95K8lJflYYHUD8Xm96OhlLvcaBQGTxU%2B3f0%3D&amp;reserved=0\" rel=\"noopener\" target=\"_blank\"> https:\/\/www.egetis.com\/wp-content\/uploads\/emcitate-full-prescribing-information.pdf<\/a><br \/><strong>\u00a0<\/strong><br \/><strong>Om Egetis Therapeutics<\/strong><br \/>Egetis Therapeutics \u00e4r ett l\u00e4kemedelsbolag i kommersiell fas med fokus p\u00e5 att utveckla och tillhandah\u00e5lla innovativa behandlingar f\u00f6r patienter med s\u00e4llsynta sjukdomar d\u00e4r det finns betydande medicinska behov. <\/p>\n<p>Genom att kombinera vetenskaplig och klinisk expertis med integrerade kompetenser inom sen klinisk utveckling, regulatoriska processer, kommersialisering och tillverkning \u00e4r Egetis engagerat i att tillhandah\u00e5lla behandlingar och dedikerat st\u00f6d till patientgrupper med stora medicinska behov och begr\u00e4nsade behandlingsalternativ. Bolagets ledande produkt, EMCITATE\u00ae (tiratricol), \u00e4r den f\u00f6rsta och enda godk\u00e4nda behandlingen f\u00f6r MCT8-brist, en s\u00e4llsynt och livsf\u00f6rkortande genetisk sjukdom, med marknadsgodk\u00e4nnande i EU och i USA.<\/p>\n<p>Med huvudkontor i Stockholm och verksamhet i USA och Europa bygger Egetis ett h\u00e5llbart globalt l\u00e4kemedelsbolag inom s\u00e4llsynta sjukdomar. F\u00f6r mer information, bes\u00f6k www.<a href=\"http:\/\/www.egetis.com\" rel=\"noopener\" target=\"_blank\">egetis.com<\/a> och f\u00f6lj Bolaget p\u00e5 LinkedIn.<br \/><strong><br \/><\/strong><strong>About PANTHERx Rare<\/strong><br \/>PANTHERx Rare makes rare disease care more personalized and less overwhelming by focusing on each patient and each therapy. PANTHERx experts develop relationships with patients, prescribers and pharmaceutical partners, serving as trusted advocates to support collaboration and care. Founded in Pittsburgh, Pennsylvania, in 2011, PANTHERx has grown into the largest independent rare pharmacy in the U.S. PANTHERx is licensed in all 50 states and U.S. territories and was the first national pharmacy to achieve dual rare disease accreditations from the Accreditation Commission for Health Care (ACHC) and the Utilization Review Accreditation Commission (URAC). PANTHERx received the 2026 MMIT Patient Choice Award for patient satisfaction, marking its ninth win.<\/p>\n<p>F\u00f6r mer information, bes\u00f6k <a href=\"http:\/\/www.pantherxrare.com\" rel=\"noopener\" target=\"_blank\">www.pantherxrare.com.<\/a><br \/><strong>\u00a0<\/strong><br \/><strong>F\u00f6r mer information, v\u00e4nligen kontakta<\/strong><br \/>Nicklas Westerholm, CEO<br \/>+46 (0) 733 542 062<br \/><a href=\"mailto:nicklas.westerholm@egetis.com\" rel=\"noopener\" target=\"_blank\">nicklas.westerholm@egetis.com<\/a><\/p>\n<p>Karl H\u00e5rd, Head of Investor Relations, Communications &amp; Business Development<br \/>+46 (0) 733 011 944<br \/><a href=\"mailto:karl.hard@egetis.com\" rel=\"noopener\" target=\"_blank\">karl.hard@egetis.com<\/a><br \/><strong>\u00a0<\/strong><br \/><strong>Fram\u00e5tblickande uttalanden<\/strong><br \/>Detta pressmeddelande inneh\u00e5ller fram\u00e5tblickande uttalanden i den mening som avses i till\u00e4mplig v\u00e4rdepapperslagstiftning, inklusive uttalanden avseende kommersialiseringen och tillg\u00e4ngligheten av Emcitate\u00ae (tiratricol) i USA, tidpunkten f\u00f6r och utfallet av en eventuell monetisering av Priority Review Voucher f\u00f6r s\u00e4llsynta pediatriska sjukdomar (Rare Pediatric Disease Priority Review Voucher), den f\u00f6rv\u00e4ntade kapaciteten i Bolagets infrastruktur f\u00f6r patient\u00e5tkomst och distribution, de f\u00f6rv\u00e4ntade f\u00f6rdelarna med Emcitate f\u00f6r patienter med MCT8-brist samt Bolagets \u00f6vergripande strategiska planer f\u00f6r utveckling och kommersialisering av behandlingar f\u00f6r s\u00e4llsynta sjukdomar. Fram\u00e5tblickande uttalanden kan i allm\u00e4nhet identifieras genom ord s\u00e5som \u201df\u00f6rv\u00e4ntar\u201d, \u201dbed\u00f6mer\u201d, \u201davser\u201d, \u201danser\u201d, \u201duppskattar\u201d, \u201dplanerar\u201d, \u201dkommer att\u201d, \u201dkan\u201d, \u201dskulle kunna\u201d, \u201dpotentiell\u201d eller liknande uttryck, \u00e4ven om inte alla fram\u00e5tblickande uttalanden inneh\u00e5ller s\u00e5dana ord.<br \/>Dessa uttalanden baseras p\u00e5 Bolagets nuvarande f\u00f6rv\u00e4ntningar, antaganden och bed\u00f6mningar per dagen f\u00f6r detta pressmeddelande och \u00e4r f\u00f6rem\u00e5l f\u00f6r risker, os\u00e4kerhetsfaktorer och andra omst\u00e4ndigheter som kan medf\u00f6ra att faktiska resultat avviker v\u00e4sentligt fr\u00e5n dem som uttryckligen eller underf\u00f6rst\u00e5tt anges i uttalandena. S\u00e5dana faktorer omfattar, men \u00e4r inte begr\u00e4nsade till, risker relaterade till den kommersiella lanseringen av och marknadsacceptansen f\u00f6r Emcitate i USA, Bolagets f\u00f6rm\u00e5ga att etablera och uppr\u00e4tth\u00e5lla en \u00e4ndam\u00e5lsenlig kommersiell infrastruktur, inklusive distributions-, patientst\u00f6ds- och ers\u00e4ttningsl\u00f6sningar, tidpunkten f\u00f6r och villkoren f\u00f6r en eventuell monetisering av Priority Review Voucher, vilken \u00e4r beroende av marknadsf\u00f6rh\u00e5llanden och tillg\u00e5ngen p\u00e5 intresserade k\u00f6pare, eventuella krav eller begr\u00e4nsningar efter marknadsgodk\u00e4nnande som kan komma att inf\u00f6ras av den amerikanska l\u00e4kemedelsmyndigheten FDA, Bolagets f\u00f6rm\u00e5ga att uppr\u00e4tth\u00e5lla regulatoriska godk\u00e4nnanden i USA och Europeiska unionen, konkurrens fr\u00e5n befintliga eller framtida behandlingar, Bolagets m\u00f6jlighet att s\u00e4kerst\u00e4lla tillr\u00e4cklig finansiering f\u00f6r sin verksamhet och sina kommersiella aktiviteter samt allm\u00e4nna ekonomiska, marknadsm\u00e4ssiga och aff\u00e4rsm\u00e4ssiga f\u00f6rh\u00e5llanden.<br \/>F\u00f6r en n\u00e4rmare beskrivning av risker och os\u00e4kerhetsfaktorer som kan p\u00e5verka Bolagets verksamhet och resultat h\u00e4nvisas till Bolagets senaste \u00e5rsredovisning samt \u00f6vriga handlingar som getts in till relevanta tillsynsmyndigheter och som finns tillg\u00e4ngliga p\u00e5 <a href=\"http:\/\/www.egetis.com.\" rel=\"noopener\" target=\"_blank\">www.egetis.com.<\/a><br \/>Bolaget \u00e5tar sig inte n\u00e5gon skyldighet att offentligt uppdatera eller revidera fram\u00e5tblickande uttalanden, vare sig till f\u00f6ljd av ny information, framtida h\u00e4ndelser eller av andra sk\u00e4l, annat \u00e4n vad som f\u00f6ljer av till\u00e4mplig lag eller regelverk.<br \/>\u00a0<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/c0ed713f-c3c4-4520-9cd1-640d580e4f7c\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-r-i-usa-for-patienter-med-mct8-brist.pdf\" rel=\"noopener\" target=\"_blank\">Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"EMCITATE \u00e4r den f\u00f6rsta och enda FDA-godk\u00e4nda behandlingen f\u00f6r perifer tyreotoxikos hos vuxna och pediatriska patienter med MCT8-brist i USA Egetis RareLink\u2122, det dedikerade patientst\u00f6dsprogrammet, erbjuder st\u00f6d kring tillg\u00e5ng till behandling, utbildning och v\u00e5rdkoordinering i samarbete med PANTHERx\u00ae Rare Pharmacy Stockholm den 27 oktober 2026 \u2013 Egetis Therapeutics AB (publ) (&#34;Egetis&#34; eller &#34;Bolaget&#34;) (Nasdaq Stockholm: [&hellip;]","protected":false},"template":"","class_list":["post-6519","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn","mfn-news-tag-mfn-ci-other","mfn-news-tag-mfn-lang-sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"EMCITATE \u00e4r den f\u00f6rsta och enda FDA-godk\u00e4nda behandlingen f\u00f6r perifer tyreotoxikos hos vuxna och pediatriska patienter med MCT8-brist i USA Egetis RareLink\u2122, det dedikerade patientst\u00f6dsprogrammet, erbjuder st\u00f6d kring tillg\u00e5ng till behandling, utbildning och v\u00e5rdkoordinering i samarbete med PANTHERx\u00ae Rare Pharmacy Stockholm den 27 oktober 2026 \u2013 Egetis Therapeutics AB (publ) (&#034;Egetis&#034; eller &#034;Bolaget&#034;) (Nasdaq Stockholm: [&hellip;]\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-27T13:23:36+00:00\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minuter\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\\\/\",\"name\":\"Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-10-27T13:00:00+00:00\",\"dateModified\":\"2026-10-27T13:23:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/","og_locale":"sv_SE","og_type":"article","og_title":"Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist - Egetis Therapeutics","og_description":"EMCITATE \u00e4r den f\u00f6rsta och enda FDA-godk\u00e4nda behandlingen f\u00f6r perifer tyreotoxikos hos vuxna och pediatriska patienter med MCT8-brist i USA Egetis RareLink\u2122, det dedikerade patientst\u00f6dsprogrammet, erbjuder st\u00f6d kring tillg\u00e5ng till behandling, utbildning och v\u00e5rdkoordinering i samarbete med PANTHERx\u00ae Rare Pharmacy Stockholm den 27 oktober 2026 \u2013 Egetis Therapeutics AB (publ) (&#34;Egetis&#34; eller &#34;Bolaget&#34;) (Nasdaq Stockholm: [&hellip;]","og_url":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2026-10-27T13:23:36+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"8 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/","url":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/","name":"Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-10-27T13:00:00+00:00","dateModified":"2026-10-27T13:23:36+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":6512,"date":"2026-10-21T16:00:00","date_gmt":"2026-10-21T16:00:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/"},"modified":"2026-10-27T13:23:36","modified_gmt":"2026-10-27T13:23:36","slug":"egetis-nomination-committee-for-the-2027-annual-general-meeting","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/","title":{"rendered":"Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting"},"content":{"rendered":"<div class=\"mfn-body\">\n<p><strong>Stockholm, Sweden, October 21, 2026. <\/strong>Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced the composition of the Nomination Committee for the 2027 Annual General Meeting (AGM) to be held on May 12, 2027. <\/p>\n<p>The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting held on April 14, 2026, comprises the following members:<\/p>\n<p>James Brush, appointed by Frazier Life Sciences<br \/>Peter Lindell, appointed by Cidro F\u00f6rvaltning AB<br \/>Peder Walberg, appointed by Cetoros AB<\/p>\n<p>Mats Blom, Chairman of the Board of Directors, will co-opt to the Nomination Committee.<\/p>\n<p>The Committee&#39;s assignment is to present proposals regarding Chairman and other members of the Board, as well as remuneration to the Board\u00b4s members, to the AGM. The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals regarding the process to appoint the Nomination Committee to the AGM in 2028.<\/p>\n<p>Shareholders who wish to submit proposals to the Nomination Committee can do so by email to <a href=\"mailto:info@egetis.com\" rel=\"noopener\" target=\"_blank\">info@egetis.com<\/a> (please label emails \u2018Nomination Committee\u2019). Proposals should be submitted no later than January 22, 2027.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-ec3fd745d984\">\n<p><strong class=\"mfn-heading-1\">For further information, please contact<\/strong><\/p>\n<hr\/>\n<p>Karl H\u00e5rd, Head of Investor Relations, Communications &amp; Business Development<br \/>Lena Wange, Investor Relations Director<br \/><a href=\"mailto:ir@egetis.com\" rel=\"noopener\" target=\"_blank\">ir@egetis.com<\/a> <\/p>\n<\/div>\n<div class=\"mfn-footer mfn-cef580f51688\">\n<p><strong class=\"mfn-heading-1\">About Egetis Therapeutics<\/strong><\/p>\n<hr\/>\n<p>Egetis Therapeutics is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need. Combining scientific and clinical expertise with integrated late-stage development, regulatory and commercial capabilities and manufacturing expertise, Egetis is committed to delivering treatments and dedicated support to underserved patient communities.<br \/>The Company&#39;s lead product, EMCITATE\u00ae (tiratricol), is the first and only approved treatment for MCT8 deficiency, a rare and life-shortening genetic disorder, with marketing authorizations in the European Union and in the United States.<br \/>Headquartered in Stockholm, Sweden, with operations in the U.S. and Europe, Egetis is building a sustainable global rare disease company.<br \/>For more information, visit egetis.com and follow the Company on LinkedIn.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Attachments<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/e0771fb3-5303-4fdf-9536-ee251d67628d\/egetis-nomination-committee-for-the-2027-annual-general-meeting.pdf\" rel=\"noopener\" target=\"_blank\">Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"Stockholm, Sweden, October 21, 2026. Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced the composition of the Nomination Committee for the 2027 Annual General Meeting (AGM) to be held on May 12, 2027. The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting held on April [&hellip;]","protected":false},"template":"","class_list":["post-6512","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn","mfn-news-tag-mfn-ci-nomination"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"Stockholm, Sweden, October 21, 2026. Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced the composition of the Nomination Committee for the 2027 Annual General Meeting (AGM) to be held on May 12, 2027. The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting held on April [&hellip;]\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-27T13:23:36+00:00\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-nomination-committee-for-the-2027-annual-general-meeting\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-nomination-committee-for-the-2027-annual-general-meeting\\\/\",\"name\":\"Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-10-21T16:00:00+00:00\",\"dateModified\":\"2026-10-27T13:23:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-nomination-committee-for-the-2027-annual-general-meeting\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-nomination-committee-for-the-2027-annual-general-meeting\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-nomination-committee-for-the-2027-annual-general-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/","og_locale":"sv_SE","og_type":"article","og_title":"Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting - Egetis Therapeutics","og_description":"Stockholm, Sweden, October 21, 2026. Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced the composition of the Nomination Committee for the 2027 Annual General Meeting (AGM) to be held on May 12, 2027. The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting held on April [&hellip;]","og_url":"https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2026-10-27T13:23:36+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/","url":"https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/","name":"Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-10-21T16:00:00+00:00","dateModified":"2026-10-27T13:23:36+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6512","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6512"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":6513,"date":"2026-10-21T16:00:00","date_gmt":"2026-10-21T16:00:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/"},"modified":"2026-10-27T13:23:36","modified_gmt":"2026-10-27T13:23:36","slug":"egetis-valberedning-utsedd-infor-arsstamman-2027","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/","title":{"rendered":"Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027"},"content":{"rendered":"<div class=\"mfn-body\">\n<p><strong>Stockholm den 21 oktober 2026.<\/strong> Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) meddelade idag sammans\u00e4ttningen av valberedningen inf\u00f6r \u00e5rsst\u00e4mman som kommer att h\u00e5llas den 12 maj 2027.<\/p>\n<p>Valberedningen, som har utsetts i enlighet med de principer som antogs av \u00e5rsst\u00e4mman den 14 april 2026, best\u00e5r av f\u00f6ljande medlemmar:<\/p>\n<p>James Brush, utn\u00e4mnd av Frazier Life Sciences<br \/>Peter Lindell, utn\u00e4mnd av Cidro F\u00f6rvaltning AB<br \/>Peder Walberg, utn\u00e4mnd av Cetoros AB<\/p>\n<p>Styrelsens ordf\u00f6rande Mats Blom \u00e4r adjungerad till valberedningen.<\/p>\n<p>Valberedningens uppgift \u00e4r att presentera f\u00f6rslag ang\u00e5ende ordf\u00f6randen och \u00f6vriga medlemmar i styrelsen, samt ers\u00e4ttning till styrelsens medlemmar, till \u00e5rsst\u00e4mman. Valberedningen ska \u00e4ven l\u00e4mna f\u00f6rslag ang\u00e5ende utn\u00e4mning och ers\u00e4ttning av revisorer. Vidare ska valberedningen l\u00e4mna f\u00f6rslag ang\u00e5ende processen f\u00f6r att utse valberedningen till \u00e5rsst\u00e4mman 2028.<\/p>\n<p>Aktie\u00e4gare som \u00f6nskar l\u00e4mna f\u00f6rslag till valberedningen kan g\u00f6ra det via e-post till info@egetis.com (v\u00e4nligen m\u00e4rk e-postmeddelanden med &#39;Valberedningen&#39;). F\u00f6rslag ska vara inl\u00e4mnade senast den 22 januari 2027.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-ec3fd745d984\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r ytterligare information, v\u00e4nligen kontakta<\/strong><\/p>\n<hr\/>\n<p>Karl H\u00e5rd, Head of Investor Relations, Communications &amp; Business Development<br \/>Lena Wange, Investor Relations Director<br \/><a href=\"mailto:ir@egetis.com\" rel=\"noopener\" target=\"_blank\">ir@egetis.com<\/a>  <\/p>\n<\/div>\n<div class=\"mfn-footer mfn-cef580f51688\">\n<p><strong class=\"mfn-heading-1\">Om Egetis Therapeutics<\/strong><\/p>\n<hr\/>\n<p>Egetis Therapeutics \u00e4r ett l\u00e4kemedelsbolag i kommersiell fas med fokus p\u00e5 att utveckla och tillhandah\u00e5lla innovativa behandlingar f\u00f6r patienter med s\u00e4llsynta sjukdomar d\u00e4r det finns betydande medicinska behov. <br \/>Genom att kombinera vetenskaplig och klinisk expertis med integrerade kompetenser inom sen klinisk utveckling, regulatoriska processer, kommersialisering och tillverkning \u00e4r Egetis engagerat i att tillhandah\u00e5lla behandlingar och dedikerat st\u00f6d till patientgrupper med stora medicinska behov och begr\u00e4nsade behandlingsalternativ. <br \/>Bolagets ledande produkt, EMCITATE\u00ae (tiratricol), \u00e4r den f\u00f6rsta och enda godk\u00e4nda behandlingen f\u00f6r MCT8-brist, en s\u00e4llsynt och livsf\u00f6rkortande genetisk sjukdom, med marknadsgodk\u00e4nnande i EU och i USA. <br \/>Med huvudkontor i Stockholm och verksamhet i USA och Europa bygger Egetis ett h\u00e5llbart globalt l\u00e4kemedelsbolag inom s\u00e4llsynta sjukdomar.<br \/>F\u00f6r mer information, bes\u00f6k egetis.com och f\u00f6lj bolaget p\u00e5 LinkedIn.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/d8486af4-1140-4613-8531-279cdf1fe3bc\/egetis-valberedning-utsedd-infor-arsstamman-2027.pdf\" rel=\"noopener\" target=\"_blank\">Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"Stockholm den 21 oktober 2026. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) meddelade idag sammans\u00e4ttningen av valberedningen inf\u00f6r \u00e5rsst\u00e4mman som kommer att h\u00e5llas den 12 maj 2027. Valberedningen, som har utsetts i enlighet med de principer som antogs av \u00e5rsst\u00e4mman den 14 april 2026, best\u00e5r av f\u00f6ljande medlemmar: James Brush, utn\u00e4mnd av Frazier Life SciencesPeter [&hellip;]","protected":false},"template":"","class_list":["post-6513","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn","mfn-news-tag-mfn-ci-nomination","mfn-news-tag-mfn-lang-sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027 - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027 - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"Stockholm den 21 oktober 2026. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) meddelade idag sammans\u00e4ttningen av valberedningen inf\u00f6r \u00e5rsst\u00e4mman som kommer att h\u00e5llas den 12 maj 2027. Valberedningen, som har utsetts i enlighet med de principer som antogs av \u00e5rsst\u00e4mman den 14 april 2026, best\u00e5r av f\u00f6ljande medlemmar: James Brush, utn\u00e4mnd av Frazier Life SciencesPeter [&hellip;]\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-27T13:23:36+00:00\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-valberedning-utsedd-infor-arsstamman-2027\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-valberedning-utsedd-infor-arsstamman-2027\\\/\",\"name\":\"Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027 - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-10-21T16:00:00+00:00\",\"dateModified\":\"2026-10-27T13:23:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-valberedning-utsedd-infor-arsstamman-2027\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-valberedning-utsedd-infor-arsstamman-2027\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-valberedning-utsedd-infor-arsstamman-2027\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027 - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/","og_locale":"sv_SE","og_type":"article","og_title":"Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027 - Egetis Therapeutics","og_description":"Stockholm den 21 oktober 2026. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) meddelade idag sammans\u00e4ttningen av valberedningen inf\u00f6r \u00e5rsst\u00e4mman som kommer att h\u00e5llas den 12 maj 2027. Valberedningen, som har utsetts i enlighet med de principer som antogs av \u00e5rsst\u00e4mman den 14 april 2026, best\u00e5r av f\u00f6ljande medlemmar: James Brush, utn\u00e4mnd av Frazier Life SciencesPeter [&hellip;]","og_url":"https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2026-10-27T13:23:36+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/","url":"https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/","name":"Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027 - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-10-21T16:00:00+00:00","dateModified":"2026-10-27T13:23:36+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6513","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6513"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":6510,"date":"2026-10-16T13:08:00","date_gmt":"2026-10-16T13:08:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/international-retrospective-cohort-study-published-on-molecular-mechanisms-underlying-the-effectiveness-of-tiratricol-in-patients-with-resistance-to-thyroid-hormone-beta-rth-beta\/"},"modified":"2026-10-27T13:23:36","modified_gmt":"2026-10-27T13:23:36","slug":"international-retrospective-cohort-study-published-on-molecular-mechanisms-underlying-the-effectiveness-of-tiratricol-in-patients-with-resistance-to-thyroid-hormone-beta-rth-beta","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/international-retrospective-cohort-study-published-on-molecular-mechanisms-underlying-the-effectiveness-of-tiratricol-in-patients-with-resistance-to-thyroid-hormone-beta-rth-beta\/","title":{"rendered":"International retrospective cohort study published on &#8220;molecular mechanisms underlying the effectiveness of tiratricol in patients with resistance to thyroid hormone beta (RTH-beta)&#8221;"},"content":{"rendered":"<div class=\"mfn-body\">\n<p><strong>Stockholm, Sweden, October 16, 2026.<\/strong> Egetis Therapeutics AB (publ) (\u201cEgetis\u201d or the \u201cCompany\u201d) (NASDAQ Stockholm: EGTX), today announced the publication (Liao, Marelli et al. 2026; <a href=\"https:\/\/www.thelancet.com\/journals\/ebiom\/article\/PIIS2352-3964(26)00396-8\/fulltext\" rel=\"noopener\" target=\"_blank\">https:\/\/www.thelancet.com\/journals\/ebiom\/article\/PIIS2352-3964(26)00396-8\/fulltext<\/a>) of the largest retrospective cohort study to date of patients with resistance to thyroid hormone beta (RTH-beta) treated with tiratricol (triiodothyroacetic acid or Triac), providing an integrated characterization of the effectiveness and molecular mechanisms of tiratricol in RTH-beta.<\/p>\n<p>The study, led by Erasmus Medical Center, Rotterdam, The Netherlands, included 28 patients aged 0.4 to 73 years, with 18 different thyroid hormone receptor beta (<em>THRB<\/em>) mutations, treated at six centres in four countries. Median treatment lasted about four years (50 months). Tiratricol lowered thyroid stimulating hormone (TSH) and free thyroxine (FT4). Mean FT4 decreased 37% (p&lt;0.0001) and mean TSH decreased by 43% (p&lt;0.0001) together with reductions in heart rate of 10 bpm (p=0.014), known to be associated with the lowering of thyrotoxicosis. The authors conclude that the study provides further support to the recommendations for tiratricol treatment in the guidelines by the European Thyroid Association and may support prospective clinical trials.<\/p>\n<p><strong>Nicklas Westerholm, CEO of Egetis Therapeutics, said:<\/strong> \u201c<em>We are encouraged to see these important data published in a leading peer-reviewed journal. As the largest retrospective study of tiratricol in patients with RTH-beta conducted to date, the findings provide valuable insights of both the potential clinical effects and underlying mechanism of action of tiratricol across a broad range of THRB mutations. Together with the significant unmet medical need in RTH-beta, these results further strengthen the scientific rationale for continued development of tiratricol in this patient population.\u201d<\/em><\/p>\n<p>As previously communicated, work is ongoing at Egetis to finalize the development plan for tiratricol in RTH-beta where scientific advisory boards have been convened and preparations for regulatory interactions are ongoing. RTH-beta is a distinct indication, with no overlap in patient populations with MCT8 deficiency. Tiratricol is not currently licensed for treatment of RTH-beta.<\/p>\n<p><strong>About resistance to thyroid hormone beta<\/strong><br \/>Resistance to Thyroid Hormone Beta (RTH-beta) is a rare inherited disorder caused by mutations in the <em>THRB<\/em> gene, leading to impaired thyroid hormone receptor beta (TR-beta) signalling. RTH-beta occurs equally in males and females. As a result of impaired TR-beta-mediated feedback regulation of the hypothalamic-pituitary-thyroid (HPT) axis, patients present with elevated circulating thyroid hormone levels, leading to clinical manifestations affecting multiple organ systems.<\/p>\n<p>Patients with RTH-beta may present with goiter, as well as cardiovascular, metabolic, and neurocognitive manifestations. Recent evidence from independent patient cohort studies suggests increased cardiovascular morbidity in patients with RTH-beta. These studies report reduced life expectancy compared with the general population, with higher free thyroid hormone T4 (FT4) concentrations being associated with mortality and\/or major cardiovascular events.<\/p>\n<p>The incidence of RTH-beta is estimated to be between 1 per 20,000-40,000 live births. There are currently no approved therapies for RTH-beta, representing a significant unmet medical need. Tiratricol has been granted Orphan Drug Designation for the treatment of RTH-beta in both the United States and the European Union.<\/p>\n<p><strong>Reference:<\/strong> W. Liao, F. Marelli, et al. Molecular mechanisms underlying the effectiveness of triiodothyroacetic acid (Triac) in patients with resistance to thyroid hormone \u03b2 (RTH\u03b2): a multicentre, international, retrospective cohort study, <a href=\"https:\/\/www.thelancet.com\/journals\/ebiom\/article\/PIIS2352-3964(26)00396-8\/fulltext\" rel=\"noopener\" target=\"_blank\">eBioMedicine 2026;133: 106512<\/a><\/p>\n<p><strong>Disclaimer: <\/strong>Erasmus Medical Center is Egetis\u2019 licensor and receives royalties from Egetis; certain authors have received fees from Egetis. Egetis had no influence on the conduct or analysis of the study.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-cef580f51688\">\n<p><strong class=\"mfn-heading-1\">About Egetis Therapeutics<\/strong><\/p>\n<hr\/>\n<p>Egetis Therapeutics is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need. Combining scientific and clinical expertise with integrated late-stage development, regulatory and commercial capabilities and manufacturing expertise, Egetis is committed to delivering treatments and dedicated support to underserved patient communities.<br \/>The Company&#39;s lead product, EMCITATE\u00ae (tiratricol), is the first and only approved treatment for MCT8 deficiency, a rare and life-shortening genetic disorder, with marketing authorizations in the European Union and in the United States.<br \/>Headquartered in Stockholm, Sweden, with operations in the U.S. and Europe, Egetis is building a sustainable global rare disease company.<br \/>For more information, visit egetis.com and follow the Company on LinkedIn.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-9916b4d0a4f8\">\n<p><strong class=\"mfn-heading-1\">For further information, please contact:<\/strong><\/p>\n<hr\/>\n<p>Nicklas Westerholm, CEO<br \/>+46 (0) 733 542 062<br \/>nicklas.westerholm@egetis.com<\/p>\n<p>Karl H\u00e5rd, Head of Investor Relations, Communications &amp; Business Development<br \/>+46 (0) 733 011 944<br \/>karl.hard@egetis.com\u00a0<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Attachments<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/1d50cad9-b2b2-421d-9e13-20d77e859a1a\/international-retrospective-cohort-study-published-on-molecular-mechanisms-underlying-the-effectiveness-of-tiratricol-in-patients-with-resistance-to-thyroid-hormone-beta-rth-beta.pdf\" rel=\"noopener\" target=\"_blank\">International retrospective cohort study published on &#34;molecular mechanisms underlying the effectiveness of tiratricol in patients with resistance to thyroid hormone beta (RTH-beta)&#34;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"Stockholm, Sweden, October 16, 2026. Egetis Therapeutics AB (publ) (\u201cEgetis\u201d or the \u201cCompany\u201d) (NASDAQ Stockholm: EGTX), today announced the publication (Liao, Marelli et al. 2026; https:\/\/www.thelancet.com\/journals\/ebiom\/article\/PIIS2352-3964(26)00396-8\/fulltext) of the largest retrospective cohort study to date of patients with resistance to thyroid hormone beta (RTH-beta) treated with tiratricol (triiodothyroacetic acid or Triac), providing an integrated characterization of [&hellip;]","protected":false},"template":"","class_list":["post-6510","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>International retrospective cohort study published on &quot;molecular mechanisms underlying the effectiveness of tiratricol in patients with resistance to thyroid hormone beta (RTH-beta)&quot; - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/international-retrospective-cohort-study-published-on-molecular-mechanisms-underlying-the-effectiveness-of-tiratricol-in-patients-with-resistance-to-thyroid-hormone-beta-rth-beta\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"International retrospective cohort study published on &quot;molecular mechanisms underlying the effectiveness of tiratricol in patients with resistance to thyroid hormone beta (RTH-beta)&quot; - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"Stockholm, Sweden, October 16, 2026. Egetis Therapeutics AB (publ) (\u201cEgetis\u201d or the \u201cCompany\u201d) (NASDAQ Stockholm: EGTX), today announced the publication (Liao, Marelli et al. 2026; https:\/\/www.thelancet.com\/journals\/ebiom\/article\/PIIS2352-3964(26)00396-8\/fulltext) of the largest retrospective cohort study to date of patients with resistance to thyroid hormone beta (RTH-beta) treated with tiratricol (triiodothyroacetic acid or Triac), providing an integrated characterization of [&hellip;]\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/international-retrospective-cohort-study-published-on-molecular-mechanisms-underlying-the-effectiveness-of-tiratricol-in-patients-with-resistance-to-thyroid-hormone-beta-rth-beta\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-27T13:23:36+00:00\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minuter\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/international-retrospective-cohort-study-published-on-molecular-mechanisms-underlying-the-effectiveness-of-tiratricol-in-patients-with-resistance-to-thyroid-hormone-beta-rth-beta\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/international-retrospective-cohort-study-published-on-molecular-mechanisms-underlying-the-effectiveness-of-tiratricol-in-patients-with-resistance-to-thyroid-hormone-beta-rth-beta\\\/\",\"name\":\"International retrospective cohort study published on \\\"molecular mechanisms underlying the effectiveness of tiratricol in patients with resistance to thyroid hormone beta (RTH-beta)\\\" - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-10-16T13:08:00+00:00\",\"dateModified\":\"2026-10-27T13:23:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/international-retrospective-cohort-study-published-on-molecular-mechanisms-underlying-the-effectiveness-of-tiratricol-in-patients-with-resistance-to-thyroid-hormone-beta-rth-beta\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/international-retrospective-cohort-study-published-on-molecular-mechanisms-underlying-the-effectiveness-of-tiratricol-in-patients-with-resistance-to-thyroid-hormone-beta-rth-beta\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/international-retrospective-cohort-study-published-on-molecular-mechanisms-underlying-the-effectiveness-of-tiratricol-in-patients-with-resistance-to-thyroid-hormone-beta-rth-beta\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"International retrospective cohort study published on &#8220;molecular mechanisms underlying the effectiveness of tiratricol in patients with resistance to thyroid hormone beta (RTH-beta)&#8221;\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"International retrospective cohort study published on \"molecular mechanisms underlying the effectiveness of tiratricol in patients with resistance to thyroid hormone beta (RTH-beta)\" - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/international-retrospective-cohort-study-published-on-molecular-mechanisms-underlying-the-effectiveness-of-tiratricol-in-patients-with-resistance-to-thyroid-hormone-beta-rth-beta\/","og_locale":"sv_SE","og_type":"article","og_title":"International retrospective cohort study published on \"molecular mechanisms underlying the effectiveness of tiratricol in patients with resistance to thyroid hormone beta (RTH-beta)\" - Egetis Therapeutics","og_description":"Stockholm, Sweden, October 16, 2026. Egetis Therapeutics AB (publ) (\u201cEgetis\u201d or the \u201cCompany\u201d) (NASDAQ Stockholm: EGTX), today announced the publication (Liao, Marelli et al. 2026; https:\/\/www.thelancet.com\/journals\/ebiom\/article\/PIIS2352-3964(26)00396-8\/fulltext) of the largest retrospective cohort study to date of patients with resistance to thyroid hormone beta (RTH-beta) treated with tiratricol (triiodothyroacetic acid or Triac), providing an integrated characterization of [&hellip;]","og_url":"https:\/\/www.egetis.com\/sv\/news\/international-retrospective-cohort-study-published-on-molecular-mechanisms-underlying-the-effectiveness-of-tiratricol-in-patients-with-resistance-to-thyroid-hormone-beta-rth-beta\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2026-10-27T13:23:36+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"4 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/international-retrospective-cohort-study-published-on-molecular-mechanisms-underlying-the-effectiveness-of-tiratricol-in-patients-with-resistance-to-thyroid-hormone-beta-rth-beta\/","url":"https:\/\/www.egetis.com\/sv\/news\/international-retrospective-cohort-study-published-on-molecular-mechanisms-underlying-the-effectiveness-of-tiratricol-in-patients-with-resistance-to-thyroid-hormone-beta-rth-beta\/","name":"International retrospective cohort study published on \"molecular mechanisms underlying the effectiveness of tiratricol in patients with resistance to thyroid hormone beta (RTH-beta)\" - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-10-16T13:08:00+00:00","dateModified":"2026-10-27T13:23:36+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/international-retrospective-cohort-study-published-on-molecular-mechanisms-underlying-the-effectiveness-of-tiratricol-in-patients-with-resistance-to-thyroid-hormone-beta-rth-beta\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/international-retrospective-cohort-study-published-on-molecular-mechanisms-underlying-the-effectiveness-of-tiratricol-in-patients-with-resistance-to-thyroid-hormone-beta-rth-beta\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/international-retrospective-cohort-study-published-on-molecular-mechanisms-underlying-the-effectiveness-of-tiratricol-in-patients-with-resistance-to-thyroid-hormone-beta-rth-beta\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"International retrospective cohort study published on &#8220;molecular mechanisms underlying the effectiveness of tiratricol in patients with resistance to thyroid hormone beta (RTH-beta)&#8221;"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":6511,"date":"2026-10-16T13:08:00","date_gmt":"2026-10-16T13:08:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/internationell-retrospektiv-kohortstudie-publicerad-om-de-molekylara-mekanismer-som-ligger-bakom-tiratricols-effekt-hos-patienter-med-resistens-mot-skoldkortelhormon-beta-rth-beta\/"},"modified":"2026-10-27T13:23:36","modified_gmt":"2026-10-27T13:23:36","slug":"internationell-retrospektiv-kohortstudie-publicerad-om-de-molekylara-mekanismer-som-ligger-bakom-tiratricols-effekt-hos-patienter-med-resistens-mot-skoldkortelhormon-beta-rth-beta","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/internationell-retrospektiv-kohortstudie-publicerad-om-de-molekylara-mekanismer-som-ligger-bakom-tiratricols-effekt-hos-patienter-med-resistens-mot-skoldkortelhormon-beta-rth-beta\/","title":{"rendered":"Internationell retrospektiv kohortstudie publicerad om &#8220;de molekyl\u00e4ra mekanismer som ligger bakom tiratricols effekt hos patienter med resistens mot sk\u00f6ldk\u00f6rtelhormon beta (RTH-beta)&#8221;"},"content":{"rendered":"<div class=\"mfn-body\">\n<p><strong>Stockholm, 16 oktober 2026.<\/strong> Egetis Therapeutics AB (publ) (\u201dEgetis\u201d eller \u201dBolaget\u201d) (Nasdaq Stockholm: EGTX) meddelade idag att den hittills st\u00f6rsta studien i patienter med resistens mot sk\u00f6ldk\u00f6rtelhormon beta (RTH-beta) som behandlats med tiratricol (triiodothyroacetic acid eller Triac) har publicerats (Liao, Marelli et al. 2026; <a href=\"https:\/\/www.thelancet.com\/journals\/ebiom\/article\/PIIS2352-3964(26)00396-8\/fulltext\" rel=\"noopener\" target=\"_blank\">https:\/\/www.thelancet.com\/journals\/ebiom\/article\/PIIS2352-3964(26)00396-8\/fulltext<\/a>). Studien ger en integrerad karakterisering av tiratricols kliniska effekt och underliggande molekyl\u00e4ra verkningsmekanismer i patienter med RTH-beta.<\/p>\n<p>Studien, som leddes av Erasmus Medical Center i Rotterdam, Nederl\u00e4nderna, omfattade 28 patienter i \u00e5ldrarna 0,4 till 73 \u00e5r med 18 olika mutationer i genen f\u00f6r sk\u00f6ldk\u00f6rtelhormonreceptorn beta (<em>THRB<\/em>), behandlade vid sex centra i fyra l\u00e4nder. Medianbehandlingstiden var cirka fyra \u00e5r (50 m\u00e5nader). Tiratricol s\u00e4nkte niv\u00e5erna av tyreoideastimulerande hormon (TSH) och fritt tyroxin (FT4). Genomsnittlig FT4 minskade med 37 procent (p&lt;0,0001) och genomsnittlig TSH med 43 procent (p&lt;0,0001), samtidigt som hj\u00e4rtfrekvensen minskade med 10 slag per minut (p=0,014), vilket \u00e4r k\u00e4nt f\u00f6r att vara associerat med minskad tyrotoxikos. F\u00f6rfattarna drar slutsatsen att studien ger ytterligare st\u00f6d f\u00f6r rekommendationerna om behandling med tiratricol i riktlinjerna fr\u00e5n European Thyroid Association och kan st\u00f6dja framtida prospektiva kliniska studier.<\/p>\n<p><strong>Nicklas Westerholm, vd f\u00f6r Egetis Therapeutics, kommenterade:<\/strong> <em>\u201dVi \u00e4r mycket n\u00f6jda att se att dessa viktiga data har publicerats i en ledande vetenskaplig tidskrift. Som den st\u00f6rsta retrospektiva studien av tiratricol hos patienter med RTH-beta som genomf\u00f6rts hittills ger resultaten v\u00e4rdefulla insikter om b\u00e5de de potentiella kliniska effekterna och den underliggande verkningsmekanismen f\u00f6r tiratricol \u00f6ver ett brett spektrum av THRB-mutationer. Tillsammans med det betydande ouppfyllda medicinska behovet inom RTH-beta st\u00e4rker resultaten ytterligare den vetenskapliga grunden f\u00f6r den fortsatta utvecklingen av tiratricol f\u00f6r denna patientgrupp.\u201d<\/em><\/p>\n<p>Som tidigare kommunicerats p\u00e5g\u00e5r arbete inom Egetis f\u00f6r att slutf\u00f6ra utvecklingsplanen f\u00f6r tiratricol vid RTH-beta. Vetenskapliga r\u00e5dgivande expertm\u00f6ten har genomf\u00f6rts och f\u00f6rberedelser inf\u00f6r regulatoriska interaktioner p\u00e5g\u00e5r. RTH-beta \u00e4r en separat indikation utan \u00f6verlapp med patientpopulationen med MCT8-brist. Tiratricol \u00e4r f\u00f6r n\u00e4rvarande inte godk\u00e4nt f\u00f6r behandling av RTH-beta.<\/p>\n<p><strong>Om resistens mot sk\u00f6ldk\u00f6rtelhormon beta<\/strong><br \/>Resistens mot sk\u00f6ldk\u00f6rtelhormon beta (RTH-beta) \u00e4r en s\u00e4llsynt \u00e4rftlig sjukdom som orsakas av mutationer i <em>THRB<\/em>-genen, vilket leder till nedsatt signalering via sk\u00f6ldk\u00f6rtelhormonreceptorn beta (TR-beta). RTH-beta f\u00f6rekommer i lika h\u00f6g grad hos m\u00e4n och kvinnor. Till f\u00f6ljd av st\u00f6rd TR-beta-medierad \u00e5terkopplingsreglering av hypotalamus-hypofys-tyreoidea-axeln (HPT-axeln) uppvisar patienter f\u00f6rh\u00f6jda cirkulerande niv\u00e5er av sk\u00f6ldk\u00f6rtelhormon, vilket leder till kliniska manifestationer som p\u00e5verkar flera organsystem.<\/p>\n<p>Patienter med RTH-beta kan uppvisa struma samt kardiovaskul\u00e4ra, metabola och neurokognitiva symtom. Nya data fr\u00e5n oberoende patientkohortstudier tyder p\u00e5 \u00f6kad kardiovaskul\u00e4r sjuklighet hos patienter med RTH-beta. Dessa studier rapporterar en kortare f\u00f6rv\u00e4ntad livsl\u00e4ngd j\u00e4mf\u00f6rt med den allm\u00e4nna befolkningen, d\u00e4r h\u00f6gre koncentrationer av fritt tyreoideahormon T4 (FT4) har associerats med d\u00f6dlighet och\/eller allvarliga kardiovaskul\u00e4ra h\u00e4ndelser.<\/p>\n<p>F\u00f6rekomsten av RTH-beta uppskattas till mellan 1 per 20 000 och 1 per 40 000 levande f\u00f6dda barn. Det finns f\u00f6r n\u00e4rvarande inga godk\u00e4nda behandlingar f\u00f6r RTH-beta, vilket inneb\u00e4r ett betydande ouppfyllt medicinskt behov. Tiratricol har erh\u00e5llit s\u00e4rl\u00e4kemedelsstatus (Orphan Drug Designation) f\u00f6r behandling av RTH-beta b\u00e5de i USA och i Europeiska unionen.<\/p>\n<p><strong>Referens<\/strong><br \/>Liao W, Marelli F, Moran C et al. <em>Molecular mechanisms underlying the effectiveness of triiodothyroacetic acid (Triac) in patients with resistance to thyroid hormone \u03b2 (RTH\u03b2): a multicentre, international, retrospective cohort study<\/em>, <strong><a href=\"https:\/\/www.thelancet.com\/journals\/ebiom\/article\/PIIS2352-3964(26)00396-8\/fulltext\" rel=\"noopener\" target=\"_blank\">eBioMedicine<\/a><\/strong><a href=\"https:\/\/www.thelancet.com\/journals\/ebiom\/article\/PIIS2352-3964(26)00396-8\/fulltext\" rel=\"noopener\" target=\"_blank\"> 2026;133:106512<\/a>.<\/p>\n<p><strong>Ansvarsfriskrivning<\/strong><br \/>Erasmus Medical Center \u00e4r licensgivare till Egetis och erh\u00e5ller royaltybetalningar fr\u00e5n Egetis. Vissa av f\u00f6rfattarna har \u00e4ven erh\u00e5llit ers\u00e4ttning fr\u00e5n Egetis. Egetis har inte haft n\u00e5got inflytande \u00f6ver studiens genomf\u00f6rande eller analys.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-cef580f51688\">\n<p><strong class=\"mfn-heading-1\">Om Egetis Therapeutics<\/strong><\/p>\n<hr\/>\n<p>Egetis Therapeutics \u00e4r ett l\u00e4kemedelsbolag i kommersiell fas med fokus p\u00e5 att utveckla och tillhandah\u00e5lla innovativa behandlingar f\u00f6r patienter med s\u00e4llsynta sjukdomar d\u00e4r det finns betydande medicinska behov. <br \/>Genom att kombinera vetenskaplig och klinisk expertis med integrerade kompetenser inom sen klinisk utveckling, regulatoriska processer, kommersialisering och tillverkning \u00e4r Egetis engagerat i att tillhandah\u00e5lla behandlingar och dedikerat st\u00f6d till patientgrupper med stora medicinska behov och begr\u00e4nsade behandlingsalternativ. <br \/>Bolagets ledande produkt, EMCITATE\u00ae (tiratricol), \u00e4r den f\u00f6rsta och enda godk\u00e4nda behandlingen f\u00f6r MCT8-brist, en s\u00e4llsynt och livsf\u00f6rkortande genetisk sjukdom, med marknadsgodk\u00e4nnande i EU och i USA. <br \/>Med huvudkontor i Stockholm och verksamhet i USA och Europa bygger Egetis ett h\u00e5llbart globalt l\u00e4kemedelsbolag inom s\u00e4llsynta sjukdomar.<br \/>F\u00f6r mer information, bes\u00f6k egetis.com och f\u00f6lj bolaget p\u00e5 LinkedIn.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-9916b4d0a4f8\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r ytterligare information, v\u00e4nligen kontakta:<\/strong><\/p>\n<hr\/>\n<p>Nicklas Westerholm, vd<br \/>+46 (0) 733 542 062<br \/>nicklas.westerholm@egetis.com<br \/>\u00a0<br \/>Karl H\u00e5rd, Head of Investor Relations, Communications &amp; Business Development<br \/>+46 (0) 733 011 944<br \/>karl.hard@egetis.com<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/1c1f1657-d90b-4736-ad5a-03233ea0ccef\/internationell-retrospektiv-kohortstudie-publicerad-om-de-molekylara-mekanismer-som-ligger-bakom-tiratricols-effekt-hos-patienter-med-resistens-mot-skoldkortelhormon-beta-rth-beta.pdf\" rel=\"noopener\" target=\"_blank\">Internationell retrospektiv kohortstudie publicerad om &#34;de molekyl\u00e4ra mekanismer som ligger bakom tiratricols effekt hos patienter med resistens mot sk\u00f6ldk\u00f6rtelhormon beta (RTH-beta)&#34;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"Stockholm, 16 oktober 2026. Egetis Therapeutics AB (publ) (\u201dEgetis\u201d eller \u201dBolaget\u201d) (Nasdaq Stockholm: EGTX) meddelade idag att den hittills st\u00f6rsta studien i patienter med resistens mot sk\u00f6ldk\u00f6rtelhormon beta (RTH-beta) som behandlats med tiratricol (triiodothyroacetic acid eller Triac) har publicerats (Liao, Marelli et al. 2026; https:\/\/www.thelancet.com\/journals\/ebiom\/article\/PIIS2352-3964(26)00396-8\/fulltext). Studien ger en integrerad karakterisering av tiratricols kliniska effekt och [&hellip;]","protected":false},"template":"","class_list":["post-6511","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn","mfn-news-tag-mfn-ci-other","mfn-news-tag-mfn-lang-sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Internationell retrospektiv kohortstudie publicerad om &quot;de molekyl\u00e4ra mekanismer som ligger bakom tiratricols effekt hos patienter med resistens mot sk\u00f6ldk\u00f6rtelhormon beta (RTH-beta)&quot; - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/internationell-retrospektiv-kohortstudie-publicerad-om-de-molekylara-mekanismer-som-ligger-bakom-tiratricols-effekt-hos-patienter-med-resistens-mot-skoldkortelhormon-beta-rth-beta\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"Internationell retrospektiv kohortstudie publicerad om &quot;de molekyl\u00e4ra mekanismer som ligger bakom tiratricols effekt hos patienter med resistens mot sk\u00f6ldk\u00f6rtelhormon beta (RTH-beta)&quot; - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"Stockholm, 16 oktober 2026. Egetis Therapeutics AB (publ) (\u201dEgetis\u201d eller \u201dBolaget\u201d) (Nasdaq Stockholm: EGTX) meddelade idag att den hittills st\u00f6rsta studien i patienter med resistens mot sk\u00f6ldk\u00f6rtelhormon beta (RTH-beta) som behandlats med tiratricol (triiodothyroacetic acid eller Triac) har publicerats (Liao, Marelli et al. 2026; https:\/\/www.thelancet.com\/journals\/ebiom\/article\/PIIS2352-3964(26)00396-8\/fulltext). Studien ger en integrerad karakterisering av tiratricols kliniska effekt och [&hellip;]\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/internationell-retrospektiv-kohortstudie-publicerad-om-de-molekylara-mekanismer-som-ligger-bakom-tiratricols-effekt-hos-patienter-med-resistens-mot-skoldkortelhormon-beta-rth-beta\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-27T13:23:36+00:00\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minuter\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/internationell-retrospektiv-kohortstudie-publicerad-om-de-molekylara-mekanismer-som-ligger-bakom-tiratricols-effekt-hos-patienter-med-resistens-mot-skoldkortelhormon-beta-rth-beta\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/internationell-retrospektiv-kohortstudie-publicerad-om-de-molekylara-mekanismer-som-ligger-bakom-tiratricols-effekt-hos-patienter-med-resistens-mot-skoldkortelhormon-beta-rth-beta\\\/\",\"name\":\"Internationell retrospektiv kohortstudie publicerad om \\\"de molekyl\u00e4ra mekanismer som ligger bakom tiratricols effekt hos patienter med resistens mot sk\u00f6ldk\u00f6rtelhormon beta (RTH-beta)\\\" - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-10-16T13:08:00+00:00\",\"dateModified\":\"2026-10-27T13:23:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/internationell-retrospektiv-kohortstudie-publicerad-om-de-molekylara-mekanismer-som-ligger-bakom-tiratricols-effekt-hos-patienter-med-resistens-mot-skoldkortelhormon-beta-rth-beta\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/internationell-retrospektiv-kohortstudie-publicerad-om-de-molekylara-mekanismer-som-ligger-bakom-tiratricols-effekt-hos-patienter-med-resistens-mot-skoldkortelhormon-beta-rth-beta\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/internationell-retrospektiv-kohortstudie-publicerad-om-de-molekylara-mekanismer-som-ligger-bakom-tiratricols-effekt-hos-patienter-med-resistens-mot-skoldkortelhormon-beta-rth-beta\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Internationell retrospektiv kohortstudie publicerad om &#8220;de molekyl\u00e4ra mekanismer som ligger bakom tiratricols effekt hos patienter med resistens mot sk\u00f6ldk\u00f6rtelhormon beta (RTH-beta)&#8221;\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Internationell retrospektiv kohortstudie publicerad om \"de molekyl\u00e4ra mekanismer som ligger bakom tiratricols effekt hos patienter med resistens mot sk\u00f6ldk\u00f6rtelhormon beta (RTH-beta)\" - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/internationell-retrospektiv-kohortstudie-publicerad-om-de-molekylara-mekanismer-som-ligger-bakom-tiratricols-effekt-hos-patienter-med-resistens-mot-skoldkortelhormon-beta-rth-beta\/","og_locale":"sv_SE","og_type":"article","og_title":"Internationell retrospektiv kohortstudie publicerad om \"de molekyl\u00e4ra mekanismer som ligger bakom tiratricols effekt hos patienter med resistens mot sk\u00f6ldk\u00f6rtelhormon beta (RTH-beta)\" - Egetis Therapeutics","og_description":"Stockholm, 16 oktober 2026. Egetis Therapeutics AB (publ) (\u201dEgetis\u201d eller \u201dBolaget\u201d) (Nasdaq Stockholm: EGTX) meddelade idag att den hittills st\u00f6rsta studien i patienter med resistens mot sk\u00f6ldk\u00f6rtelhormon beta (RTH-beta) som behandlats med tiratricol (triiodothyroacetic acid eller Triac) har publicerats (Liao, Marelli et al. 2026; https:\/\/www.thelancet.com\/journals\/ebiom\/article\/PIIS2352-3964(26)00396-8\/fulltext). Studien ger en integrerad karakterisering av tiratricols kliniska effekt och [&hellip;]","og_url":"https:\/\/www.egetis.com\/sv\/news\/internationell-retrospektiv-kohortstudie-publicerad-om-de-molekylara-mekanismer-som-ligger-bakom-tiratricols-effekt-hos-patienter-med-resistens-mot-skoldkortelhormon-beta-rth-beta\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2026-10-27T13:23:36+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"4 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/internationell-retrospektiv-kohortstudie-publicerad-om-de-molekylara-mekanismer-som-ligger-bakom-tiratricols-effekt-hos-patienter-med-resistens-mot-skoldkortelhormon-beta-rth-beta\/","url":"https:\/\/www.egetis.com\/sv\/news\/internationell-retrospektiv-kohortstudie-publicerad-om-de-molekylara-mekanismer-som-ligger-bakom-tiratricols-effekt-hos-patienter-med-resistens-mot-skoldkortelhormon-beta-rth-beta\/","name":"Internationell retrospektiv kohortstudie publicerad om \"de molekyl\u00e4ra mekanismer som ligger bakom tiratricols effekt hos patienter med resistens mot sk\u00f6ldk\u00f6rtelhormon beta (RTH-beta)\" - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-10-16T13:08:00+00:00","dateModified":"2026-10-27T13:23:36+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/internationell-retrospektiv-kohortstudie-publicerad-om-de-molekylara-mekanismer-som-ligger-bakom-tiratricols-effekt-hos-patienter-med-resistens-mot-skoldkortelhormon-beta-rth-beta\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/internationell-retrospektiv-kohortstudie-publicerad-om-de-molekylara-mekanismer-som-ligger-bakom-tiratricols-effekt-hos-patienter-med-resistens-mot-skoldkortelhormon-beta-rth-beta\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/internationell-retrospektiv-kohortstudie-publicerad-om-de-molekylara-mekanismer-som-ligger-bakom-tiratricols-effekt-hos-patienter-med-resistens-mot-skoldkortelhormon-beta-rth-beta\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"Internationell retrospektiv kohortstudie publicerad om &#8220;de molekyl\u00e4ra mekanismer som ligger bakom tiratricols effekt hos patienter med resistens mot sk\u00f6ldk\u00f6rtelhormon beta (RTH-beta)&#8221;"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":6488,"date":"2026-09-30T16:00:00","date_gmt":"2026-09-30T16:00:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/changes-in-number-of-shares-and-votes-in-egetis-therapeutics\/"},"modified":"2026-10-27T13:23:36","modified_gmt":"2026-10-27T13:23:36","slug":"changes-in-number-of-shares-and-votes-in-egetis-therapeutics","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/changes-in-number-of-shares-and-votes-in-egetis-therapeutics\/","title":{"rendered":"Changes in number of shares and votes in Egetis Therapeutics"},"content":{"rendered":"<div class=\"mfn-body\">\n<p>Stockholm, Sweden, September 30, 2026. The number of shares and votes in Egetis Therapeutics AB (publ) (\u201cEgetis Therapeutics\u201d or the \u201cCompany\u201d) (Nasdaq Stockholm: EGTX) has changed in September as a result of the exercise of employee stock options granted under the 2022\u20132026 and 2023-2026 employee stock option programs.<\/p>\n<p>The total number of shares in the Company is unchanged at 490,828,605, but the number of ordinary shares has increased by 18,338, from 464,947,224 to 464,965,562 and the number of C shares has decreased by 18,338, from 25,881,381 to 25,863,043. The total number of votes in the Company has increased by 16,504.2, from 467,535, 362.1 to 467,551,866.3. <br \/>The share capital is unchanged at approximately SEK 25,833,094.110797.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-custom mfn-e28b01cfb977\">\n<p><strong class=\"mfn-heading-1\">For further information, please contact:<\/strong><\/p>\n<hr\/>\n<p>Karl H\u00e5rd, Head of Investor Relations &amp; Business Development<br \/>+46 (0) 733 011 944<br \/>karl.hard@egetis.com\u00a0<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-cef580f51688\">\n<p><strong class=\"mfn-heading-1\">About Egetis Therapeutics<\/strong><\/p>\n<hr\/>\n<p>Egetis Therapeutics is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need. Combining scientific and clinical expertise with integrated late-stage development, regulatory and commercial capabilities and manufacturing expertise, Egetis is committed to delivering treatments and dedicated support to underserved patient communities.<br \/>The Company&#39;s lead product, EMCITATE\u00ae (tiratricol), is the first and only approved treatment for MCT8 deficiency, a rare and life-shortening genetic disorder, with marketing authorizations in the European Union and in the United States.<br \/>Headquartered in Stockholm, Sweden, with operations in the U.S. and Europe, Egetis is building a sustainable global rare disease company.<br \/>For more information, visit egetis.com and follow the Company on LinkedIn.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-lhfi\">\n<p><em>This information is information that Egetis Therapeutics is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-09-30 18:00 CEST.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Attachments<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/e626d069-889a-4081-bc30-5ad7f712b7dd\/changes-in-number-of-shares-and-votes-in-egetis-therapeutics.pdf\" rel=\"noopener\" target=\"_blank\">Changes in number of shares and votes in Egetis Therapeutics<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"Stockholm, Sweden, September 30, 2026. The number of shares and votes in Egetis Therapeutics AB (publ) (\u201cEgetis Therapeutics\u201d or the \u201cCompany\u201d) (Nasdaq Stockholm: EGTX) has changed in September as a result of the exercise of employee stock options granted under the 2022\u20132026 and 2023-2026 employee stock option programs. The total number of shares in the [&hellip;]","protected":false},"template":"","class_list":["post-6488","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ca","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-regulatory-lhfi","mfn-news-tag-mfn","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-ca-shares"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Changes in number of shares and votes in Egetis Therapeutics - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/changes-in-number-of-shares-and-votes-in-egetis-therapeutics\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"Changes in number of shares and votes in Egetis Therapeutics - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"Stockholm, Sweden, September 30, 2026. The number of shares and votes in Egetis Therapeutics AB (publ) (\u201cEgetis Therapeutics\u201d or the \u201cCompany\u201d) (Nasdaq Stockholm: EGTX) has changed in September as a result of the exercise of employee stock options granted under the 2022\u20132026 and 2023-2026 employee stock option programs. The total number of shares in the [&hellip;]\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/changes-in-number-of-shares-and-votes-in-egetis-therapeutics\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-27T13:23:36+00:00\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/changes-in-number-of-shares-and-votes-in-egetis-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/changes-in-number-of-shares-and-votes-in-egetis-therapeutics\\\/\",\"name\":\"Changes in number of shares and votes in Egetis Therapeutics - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-09-30T16:00:00+00:00\",\"dateModified\":\"2026-10-27T13:23:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/changes-in-number-of-shares-and-votes-in-egetis-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/changes-in-number-of-shares-and-votes-in-egetis-therapeutics\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/changes-in-number-of-shares-and-votes-in-egetis-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Changes in number of shares and votes in Egetis Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Changes in number of shares and votes in Egetis Therapeutics - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/changes-in-number-of-shares-and-votes-in-egetis-therapeutics\/","og_locale":"sv_SE","og_type":"article","og_title":"Changes in number of shares and votes in Egetis Therapeutics - Egetis Therapeutics","og_description":"Stockholm, Sweden, September 30, 2026. The number of shares and votes in Egetis Therapeutics AB (publ) (\u201cEgetis Therapeutics\u201d or the \u201cCompany\u201d) (Nasdaq Stockholm: EGTX) has changed in September as a result of the exercise of employee stock options granted under the 2022\u20132026 and 2023-2026 employee stock option programs. The total number of shares in the [&hellip;]","og_url":"https:\/\/www.egetis.com\/sv\/news\/changes-in-number-of-shares-and-votes-in-egetis-therapeutics\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2026-10-27T13:23:36+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/changes-in-number-of-shares-and-votes-in-egetis-therapeutics\/","url":"https:\/\/www.egetis.com\/sv\/news\/changes-in-number-of-shares-and-votes-in-egetis-therapeutics\/","name":"Changes in number of shares and votes in Egetis Therapeutics - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-09-30T16:00:00+00:00","dateModified":"2026-10-27T13:23:36+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/changes-in-number-of-shares-and-votes-in-egetis-therapeutics\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/changes-in-number-of-shares-and-votes-in-egetis-therapeutics\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/changes-in-number-of-shares-and-votes-in-egetis-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"Changes in number of shares and votes in Egetis Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":6489,"date":"2026-09-30T16:00:00","date_gmt":"2026-09-30T16:00:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/forandring-av-antal-aktier-och-roster-i-egetis-therapeutics\/"},"modified":"2026-10-27T13:23:37","modified_gmt":"2026-10-27T13:23:37","slug":"forandring-av-antal-aktier-och-roster-i-egetis-therapeutics","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/forandring-av-antal-aktier-och-roster-i-egetis-therapeutics\/","title":{"rendered":"F\u00f6r\u00e4ndring av antal aktier och r\u00f6ster i Egetis Therapeutics"},"content":{"rendered":"<div class=\"mfn-body\">\n<p>Stockholm, 30 september 2026. Antalet aktier och r\u00f6ster i Egetis Therapeutics AB (publ) (\u201dEgetis Therapeutics\u201d eller \u201dBolaget\u201d) (Nasdaq Stockholm: EGTX) har f\u00f6r\u00e4ndrats under september till f\u00f6ljd av utnyttjande av personaloptioner som tilldelats inom personaloptionsprogrammen 2022\u20132026 och 2023\u20132026.<\/p>\n<p>Det totala antalet aktier i Bolaget \u00e4r of\u00f6r\u00e4ndrat och uppg\u00e5r till 490 828 605, men antalet stamaktier har \u00f6kat med 18 338, fr\u00e5n 464 947 224 till 464 965 562, och antalet C-aktier har minskat med 18 338, fr\u00e5n 25 881 381 till 25 863 043. Det totala antalet r\u00f6ster i Bolaget har \u00f6kat med 16 504,2, fr\u00e5n 467 535 362,1 till 467 551 866,3. Aktiekapitalet \u00e4r of\u00f6r\u00e4ndrat och uppg\u00e5r till cirka 25 833 094,110797 kronor.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-custom mfn-e28b01cfb977\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r ytterligare information, v\u00e4nligen kontakta:<\/strong><\/p>\n<hr\/>\n<p>Karl H\u00e5rd, Head of Investor Relations &amp; Business Development<br \/>+46 (0) 733 011 944<br \/>karl.hard@egetis.com<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-cef580f51688\">\n<p><strong class=\"mfn-heading-1\">Om Egetis Therapeutics<\/strong><\/p>\n<hr\/>\n<p>Egetis Therapeutics \u00e4r ett l\u00e4kemedelsbolag i kommersiell fas med fokus p\u00e5 att utveckla och tillhandah\u00e5lla innovativa behandlingar f\u00f6r patienter med s\u00e4llsynta sjukdomar d\u00e4r det finns betydande medicinska behov. <br \/>Genom att kombinera vetenskaplig och klinisk expertis med integrerade kompetenser inom sen klinisk utveckling, regulatoriska processer, kommersialisering och tillverkning \u00e4r Egetis engagerat i att tillhandah\u00e5lla behandlingar och dedikerat st\u00f6d till patientgrupper med stora medicinska behov och begr\u00e4nsade behandlingsalternativ. <br \/>Bolagets ledande produkt, EMCITATE\u00ae (tiratricol), \u00e4r den f\u00f6rsta och enda godk\u00e4nda behandlingen f\u00f6r MCT8-brist, en s\u00e4llsynt och livsf\u00f6rkortande genetisk sjukdom, med marknadsgodk\u00e4nnande i EU och i USA. <br \/>Med huvudkontor i Stockholm och verksamhet i USA och Europa bygger Egetis ett h\u00e5llbart globalt l\u00e4kemedelsbolag inom s\u00e4llsynta sjukdomar.<br \/>F\u00f6r mer information, bes\u00f6k egetis.com och f\u00f6lj bolaget p\u00e5 LinkedIn.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-lhfi\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Egetis Therapeutics \u00e4r skyldigt att offentligg\u00f6ra enligt lagen om handel med finansiella instrument. Informationen l\u00e4mnades f\u00f6r offentligg\u00f6rande den 2026-09-30 18:00 CEST.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/79ca1a1d-0330-43fe-b562-fa8245fb2f70\/forandring-av-antal-aktier-och-roster-i-egetis-therapeutics.pdf\" rel=\"noopener\" target=\"_blank\">F\u00f6r\u00e4ndring av antal aktier och r\u00f6ster i Egetis Therapeutics<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"Stockholm, 30 september 2026. Antalet aktier och r\u00f6ster i Egetis Therapeutics AB (publ) (\u201dEgetis Therapeutics\u201d eller \u201dBolaget\u201d) (Nasdaq Stockholm: EGTX) har f\u00f6r\u00e4ndrats under september till f\u00f6ljd av utnyttjande av personaloptioner som tilldelats inom personaloptionsprogrammen 2022\u20132026 och 2023\u20132026. Det totala antalet aktier i Bolaget \u00e4r of\u00f6r\u00e4ndrat och uppg\u00e5r till 490 828 605, men antalet stamaktier har [&hellip;]","protected":false},"template":"","class_list":["post-6489","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ca","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-regulatory-lhfi","mfn-news-tag-mfn","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-ca-shares","mfn-news-tag-mfn-lang-sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>F\u00f6r\u00e4ndring av antal aktier och r\u00f6ster i Egetis Therapeutics - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/forandring-av-antal-aktier-och-roster-i-egetis-therapeutics\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"F\u00f6r\u00e4ndring av antal aktier och r\u00f6ster i Egetis Therapeutics - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"Stockholm, 30 september 2026. Antalet aktier och r\u00f6ster i Egetis Therapeutics AB (publ) (\u201dEgetis Therapeutics\u201d eller \u201dBolaget\u201d) (Nasdaq Stockholm: EGTX) har f\u00f6r\u00e4ndrats under september till f\u00f6ljd av utnyttjande av personaloptioner som tilldelats inom personaloptionsprogrammen 2022\u20132026 och 2023\u20132026. Det totala antalet aktier i Bolaget \u00e4r of\u00f6r\u00e4ndrat och uppg\u00e5r till 490 828 605, men antalet stamaktier har [&hellip;]\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/forandring-av-antal-aktier-och-roster-i-egetis-therapeutics\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-27T13:23:37+00:00\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/forandring-av-antal-aktier-och-roster-i-egetis-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/forandring-av-antal-aktier-och-roster-i-egetis-therapeutics\\\/\",\"name\":\"F\u00f6r\u00e4ndring av antal aktier och r\u00f6ster i Egetis Therapeutics - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-09-30T16:00:00+00:00\",\"dateModified\":\"2026-10-27T13:23:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/forandring-av-antal-aktier-och-roster-i-egetis-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/forandring-av-antal-aktier-och-roster-i-egetis-therapeutics\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/forandring-av-antal-aktier-och-roster-i-egetis-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"F\u00f6r\u00e4ndring av antal aktier och r\u00f6ster i Egetis Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"F\u00f6r\u00e4ndring av antal aktier och r\u00f6ster i Egetis Therapeutics - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/forandring-av-antal-aktier-och-roster-i-egetis-therapeutics\/","og_locale":"sv_SE","og_type":"article","og_title":"F\u00f6r\u00e4ndring av antal aktier och r\u00f6ster i Egetis Therapeutics - Egetis Therapeutics","og_description":"Stockholm, 30 september 2026. Antalet aktier och r\u00f6ster i Egetis Therapeutics AB (publ) (\u201dEgetis Therapeutics\u201d eller \u201dBolaget\u201d) (Nasdaq Stockholm: EGTX) har f\u00f6r\u00e4ndrats under september till f\u00f6ljd av utnyttjande av personaloptioner som tilldelats inom personaloptionsprogrammen 2022\u20132026 och 2023\u20132026. Det totala antalet aktier i Bolaget \u00e4r of\u00f6r\u00e4ndrat och uppg\u00e5r till 490 828 605, men antalet stamaktier har [&hellip;]","og_url":"https:\/\/www.egetis.com\/sv\/news\/forandring-av-antal-aktier-och-roster-i-egetis-therapeutics\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2026-10-27T13:23:37+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/forandring-av-antal-aktier-och-roster-i-egetis-therapeutics\/","url":"https:\/\/www.egetis.com\/sv\/news\/forandring-av-antal-aktier-och-roster-i-egetis-therapeutics\/","name":"F\u00f6r\u00e4ndring av antal aktier och r\u00f6ster i Egetis Therapeutics - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-09-30T16:00:00+00:00","dateModified":"2026-10-27T13:23:37+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/forandring-av-antal-aktier-och-roster-i-egetis-therapeutics\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/forandring-av-antal-aktier-och-roster-i-egetis-therapeutics\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/forandring-av-antal-aktier-och-roster-i-egetis-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"F\u00f6r\u00e4ndring av antal aktier och r\u00f6ster i Egetis Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}]